CA2003718C - Compounds - Google Patents

Abstract

Compounds of general formula I:

(see fig. I) wherein:
R1 represents a hydrogen atom, a C1-C6 alkyl, phenyl, thiophenyl, substituted phenyl, phenyl (C1-C6) alkyl, heterocyclyl, (C1-C6) alkylcarbonyl phenacyl or substituted phenacyl group or, when n = O, R1 represents SRx, wherein Rx represents a group:

(see fig. II) R2 represents a hydrogen atom or a C1-C6 alkyl, C1-C6 alkenyl, phenyl(C1-C6)alkyl, cycloalkyl(C1-C6)alkyl or cycloalkenyl (C1-C6)alkyl group;

R3 represents an amino acid residue with R or S
stereochemistry or a C1-C6 alkyl, benzyl, (C1-C6 alkoxy)benzyl or benzyloxy(C1-C6 alkyl) group;

R4 represents a hydrogen atom or a C1-C6 alkyl group;

R5 represents a hydrogen atom or a methyl group;

n is an integer having the value 0, 1 or 2; and A represents a C1-C6 hydrocarbon chain, optionaly substituted with one or more C1-C6 alkyl, phenyl or substituted phenyl groups;

and their salts and N-oxides are coliagenase inhibitors are and useful in the management of disease involving tissue degradation and/or the promotion of wound healing. Diseases involving tissue degradation include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption diseases and tumour invasion.

Description

This invention relates to pharmaceutically and veterinarily active compounds, which are derivatives of hydroxamic acid.

The compounds of the present invention act as inhibitors of metalloproteases involved in tissue degradation, such as collagenase, which initiates collagen breakdown, stromelysin (protoglycanase), gelatinase and collagenase (IV). There is evidence implicating collagenase as one of the key enzymes in the breakdown Df articular cartilage and bone in rheumatoid arthritis (Arthritis and Rheumatism, 20, 1231 - 1239, 1977). Potent inhibitors of collagenase and other metalloproteases involved in tissue degradation are useful in the treatment of rheumatoid arthritis and related diseases in which collagenolytic activity is important. Inhibitors of metalloproteases of this type can therefore be used in treating or preventing conditions which involve tissue breakdown;
they are therefore useful in the treatment of arthropathy, dermatological conditions, bone resorption, inflammatory diseases and tumour invasion and in the promotion of wound healing. Specifically, compounds of the present invention may be useful in the treatment of osteopenias such as osteoporGsis, rheumatoid arthritis, osteoarthritis, periodontitis, gingivitis, corneal ulceration and tumour invasion.

A number of small peptide like compounds which inhibit metalloproteases have been described. Perhaps the most notable of these are those relating to the angiotensin converting enzyme (ACE) where such agents act to block the conversion of the decapeptide angiotensin I to angiotensin II a potent pressor substance. Compounds of this type are described in EP-A-0012401.

Certain hydroxamic acids have been suggested as collagenase inhibitors as in US-A-4599361 and EP-A-0236872. Other hydroxamic acids have been prepared as ACE inhibitors, for example in US-A-4105789, while still others have been described . as enkephalinase - inhibitors as in US-A-4496540.

EP-A-0012401 discloses antihypertensive compounds of the formula:

O Rl R3 R4 R5 O

R O R

wherein R and R6 are the same or different and are hydroxy, alkoxy, alkenoxy, dialkylamino alkoxy, acylamino alkoxy, acyloxy alkoxy, aryloxy, alkyloxy, substituted aryloxy or substituted aralkoxy wherein the substituent is methyl, halo, or methoxy, amino, alkylamino, dialkylamino, aralkylamino or hydroxyamino;

Rl is hydrogen, alkyl of from 1 to 20 carbon atoms, including branched, cyclic and unsaturated alkyl Z00~718 groups;

substituted alkyl wherein the substituent is halo, hydroxy, alkoxy, aryloxy amino, alkylamino, dialkyl-amino, acrylamino, arylamino, guanidino, imidazolyl, indolyl, mercapto, alkylthio, arylthio, carboxy, carboxamido, carbalkoxy, phenyl, substituted phenyl wherein the substituent is alkyl, alkoxy or halo;
aralkyl or heteroaralkyl, aralkenyl or heteroaralkenyl, substituted aralkyl, substituted heteroaralkyl, - 10 substituted aralkenyl or substituted hetereoaralkenyl, wherein the substituent is halor or dihalo, alkyl, hydroxy, alkoxy, amino, aminomethyl, acrylamino, dialkylamino, alkylamino, carboxyl, haloalkyl, cyano or - sulphonamido, aralkyl or hetereoaralkyl substituted on the alkyl portion by amino or acylamino;

R2 and R7 are hydrogen or alkyl;

R3 is hydrogen, alkyl, phenylalkyl, aminomethylphenyl-alkyl, hydroxyphenylalkyl, hydroxyalkyl, acetylamino-alkyl, acylaminoalkyl, acylaminoalkyl aminoalkyl, - dimethylaminoalkyl, haloalkyl, guanidinoalkyl, imida-zolylalkyl, indolylalkyl,~ mercaptoalkyl and alkylthio-alkyl;

R4 is hydrogen or alkyl;

R5 is hydrogen, alkyl, phenyl, phenylalkyl, hydroxy-phenylalkyl, hydroxyalkyl, aminoalkyl, guanidinoalkyl, imidazolylalkyl, indolylalkyl, mercaptoalkyl or alkyl-thioalkyl;

2003t718 R4 and R5 may be connected together to form an alkylene bridge of from 2 to 4 carbon atoms, an alkylene bridge of from 2 to 3 carbon atoms and one sulphur atom, an alkylene bridge of from 3 to 4 carbon atoms containing a double bond or an alkylene bridge as above, substituted with hydroxy, alkoxy or alkyl and the pharmaceutically acceptable salts thereof.

US-A-4599361 discloses compounds of the formula:

O O R2 ;~
: HOHNC-A-CNH-CH-CNHR

wherein R1 is Cl-C6 alkyl;
R2 is Cl-C6 alkyl, benzyl, benzyloxybenzyl, (Cl-C6 alkoxy)benzyl or benzyloxy(Cl-C6 alkyl);
a is a chiral centre with optional R or S stereo-chemistry;
A is a -(CHR3-CHR4)- group b c ~. .
or a -(CR3=CR4)- group wherein b and c are chiral centres with optional R or S stereochemistry;
R3 is hydrogen, Cl-C6 alkyl, phenyl or phenyl(Cl-C6 alkyl) and R4 is hydrogen, Cl-C6 alkyl, phenyl(C1-C6 alkyl), cycloalkyl or cycloalkyl(Cl-C6 alkyl).

EP-A-0236872 discloses generically compounds of the formula A Rl R2 R4 l l I 1 5 HC-CH-CO-NH-CH-CO-N-CH-R

wherein A represents a group of the formula HN(OI~)-CO- or HCO-N(OH)-;

Rl represents a C2-C5 alkyl group;

R2 represents the characterising group of a natural alpha-amino acid in which the functional group can be protected, amino groups may be acylated and carboxyl groups can be amidated, with the proviso that R2 can not represent hydrogen or a methyl group;

R3 represents hydrogen or an amino, hydroxy, mercapto, Cl-C6 alkyl, C1-C6 alkoxy, C1-C6 acylamino, Cl-C6-alkylthio, aryl-(Cl-C6 alkyl)-, amino-(Cl-C6-alkyl)-, hydroxy(C1-C6-alkyl)-, mercapto(C1-C6 alkyl) or carboxy(Cl-C6 alkyl) group, wherein the amino, hydroxy, mercapto or carboxyl groups can be protected and the amino groups may be acylated or the carboxyl groups may be amidated;

R4 represents hydrogen or a methyl group;

R5 represents hydrogen or a Cl-C6 acyl, Cl-C6 alkoxy-Cl-C6 alkyl, di(Cl-C6-alkoxy)methylene, carboxy, (Cl-C6 alkyl)carbonyl, (Cl-C6 alkoxy)carbOnyl~ arylmethoxy ,9~'.

-carbonyl, tCl-C6 alkyl)amino carbonyl or arylamino carbonyl group; and R6 represents hydroxy or a methylene group; or R2 and R4 together represent a group-(CTI2)n~, wherein n represents a number from 4 to 11; or R4 and R5 together represent a trimethylene group;

and pharmaceutically acceptable salts of such compounds, which are acid or basic.

US-A-4105789 generically discloses compounds which have the general formula IR3 IRl R4-oc-(cH2)n-c~-co-N-cH2-COOH
and salts thereof, wherein R1 is hydrogen, lower alkyl, phenyl lower alkylene, hydroxy-lower alkylene, hydroxyphenyl lower alkylene, amino-lower alkylene, guanidine lower alkylene, mercapto-lower alkylene, lower alkyl-mercapto-lower alkylene, imidazolyl lower alkylene, indolyl-lower alkylene or carbamoyl lower alkylene;
R2 is hydrogen or lower alkyl;
R3 is lower alkyl or phenyl lower alkylene;
R4 is hydroxy, lower alkoxy or hydroxyamino; and n is 1 or 2.

7~

Z003~18 US-A-44g6540 discloses compounds of the general - formula:

A-B-NHOH

wherein A is one of the aromatic group-containing amino acid residues L-tryptophyl, D-tryptophyl, L-tyrosyl, D-tyrosyl, L-phenylalanyl, or D-phenylalanyl, and B is one of the amino acids glycine, L-alanine, D-alanine, L-leucine, D-leucine, L-isoleucine, or D-isoleucine;
and pharmaceutically acceptable salts thereof.

It would however be desirable to improve on the solubility of known collagenase inhibitors and/or - stomelysin inhibitors (whether as the free base or the salt~ and, furthermore, increases in activity have also been sought. It is not a simple matter, however, to predict what variations in known compounds would be desirable to increase or even retain activity; certain modifications of known hydroxamic acid derivatives have been found to lead to loss of activity.

According to a first aspect of the invention, there is -- provided a compound of general formula I:
~ R3 R4 A CoNHoH
R SCn (I) wherein:

-' 2003718 .

R1 represents a Cl-C6 alkyl other than tert-butyl; phenyl;
substituted phenyl wherein the substituents are selected from C1-C6 alkyl, hydroxy, C1-C6 alkoxy, Cl-C6 alkylcarbonylamino, C1-C6 alkoxycarbonylamino and [N-(Cl-C6 alkoxycarbonylamino)-N-(Cl-C6 alkyl)] amino (Cl-C6 alkylaminocarbonylamino);thienyl; (Cl-C6) alkylcarbonyl;
or benzoyl group;

R2 represents a hydrogen atom or a C1-C6 alkyl, C2-C6 alkenyl, phenyl (Cl-C6) alkyl, cycloalkyl (Cl-C6) alkyl or cycloalkenyl (Cl-C6) alkyl group;

R3 represents an amino acid side chain, a Cl-C6 alkyl group other than an amino acid side chain, benzyl, (Cl-C6 alkoxy) benzyl or benzyloxy (C1-C6 alkyl) or benzyloxy benzyl group;

R4 represents a hydrogen atom or a C1-C6 alkyl group;

R5 represents a hydrogen atom or a methyl group;

n is an integer having the value 0, 1 or 2; and A represents a Cl-C6 hydrocarbon chain;

or a salt thereof ingestible by humans or animals.

~D

-8a- 2 0 0 3 7 1 8 Hereafter in this specification, the term "compound"
includes "salt" unless the context requires otherwise.

As used herein the term "Cl-C6 alkyl" refers to a straight or branched chain alkyl moiety having from one to six carbon atoms, including - for example, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl and hexyl, and cognate terms (such as "Cl-C6 ~. , :
. ., alkoxy") are to be construed accordingly.

The term "C2-C6 alkenyl" refers to a straight or branched chain alkyl moiety having two to six carbons and having in addition one double bond, of either E or Z stereochemistry where applicable. This term would include, for example, an alpha, beta-unsaturated methylene group, vinyl, 1-propenyl, 1- and 2-butenyl and 2-methyl-2-propenyl.

The term "cycloalkyl" refers to a saturated 1~ alicyclic moiety having from 3 to 8 carbon atoms and includes for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "cycloalkenyl" refers to an unsaturated alicycle having from 3 to 8 carbon atoms and includes cyclopropenyl, cyclobutenyl and cyclopentenyl, cyclohexenyl.

The term "substituted", as applied to a phenyl or other aromatic ring, means substituted with up to four substituents each of which independently may be C1-C6 alkyl, Cl-C6 alkoxy, hydroxy, thiol, Cl-C6 alkylthiol, amino, halo (including fluoro, chloro, bromo and iodo), triflouromethyl or nitro.

The term "amino acid side chain" means a characteristic side chain attached to the -CH(NH2)(COOH) moiety in the following R or S amino acids: glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, histidine, arginine, ,''' ~~

glutamic acid and aspartic acid.

The term "hydrocarbon chain" includes alkylene, alkenylene and alkynylene chains of from 1 to 6 carbon atoms. Preferably the carbon atom of the hydrocarbon chain nearest to the hydroxamic acid group is a methylene carbon atom.

There are several chiral centres in the compounds according to the invention because of the presence of asymmetric carbon atoms. The presence of several asymmetreic carbon atoms gives rise to a number of diastereomers with the appropriate R or S
stereochemistry at each chiral centre. General formula I and, where apprpriate, all other formulae in this spe~ification are to be understood to include alI such stereoisomers and mixtures (for example racemic mixtures) thereo~. Compounds in which the chiral centre adjacent the substituent R3 has S stereochemistry and/or the chiral centre adjacent the substituent R2 has R stereochemistry are preferred.

Further or other preferred compounds include those in which, independently or in any combination:

Rl represents a Cl-C4 alkyl other than tertbutyl, phenyl, 4-hydroxyphenyl, thienyl, acetyl or benzoyl group.

R2 represents a C3-C6 a]kyl (for example isobutyl) group;

R3 represents a benzyl or 4-(C1-C6)alkoxyphenylmethyl ~D

or benzyloxybenzyl group;

R4 represents a C1-C4 alkyl (for example methyl) group;
and R5 represents a hydrogen atom.

Particularly preferred compounds include:

1. [4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide, 2. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienyl-thiomethyl) succinyl]-L-phenylalanine-N-methylamide, 3. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(benzylthiomethyl) succinyl]-L-phenylalanine-N-methylamide, 4. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(acetylthiomethyl) succinyl]-L-phenylalanine-N-methylamide and 5. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(mercaptomethyl) succinyl]-L-phenylalanine-N-methylamide 6. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(benzoylthio-methyl)succinyl]-L-phenylalanine-N-methylamide 7. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(pivaloylthio-methyl)succinyl]-L-phenylalanine-N-methylamide lla 8. [4-(N-Hydroxyamino)-2R-isobutyl-3S-tphenylthio-methyl)succinyl]-L-phenylalanine-N-methylamide sodium salt 9. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-methoxyphenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide 10. [4-(N-Hydroxyamino)-2R-isobutyl-3S-~4-hydroxyphenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide 11. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthio-methyl)succinyl]-L-phenylalanine-N-methylamide sodium salt 12. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-methoxyphenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide sodium salt 13. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-tertbutylphenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide 14. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(2,4-dimethyl-phenylthiomethyl) succinyl]-L-phenylalanine-N-methylamide 15. ki~-S,S'-([4(N-Hydroxyamino-2R-isobutyl-3S-(thiomethyl) succinyl]-L-phenylalanine-N-methylamide) disulphide 16. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(3-bromophenylthio-methyl) succinyl]-L-phenylalanine-N-methylamide llb 17. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(3-chlorophenyl-thiomethyl) succinyl]-L-phenylalanine-N-methylamide 18. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(3-methylphenyl-thiomethyl) succinyl]-L-phenylalanine-N-methylamide 19. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(N-acetyl)-aminophenylthiomethyl)succinyl}-L-phenylalanine-N-methylamide 20. [4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylsulphinyl-methylsuccinyl]-L-phenylalanine-N-methylamide 21. [4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylsulphonyl-methylsuccinyl]-L-phenylalanine-N-methylamide 22. [4-(N-Hydroxyamino)-2R-isobutyl-3S-2-thienylsulphinyl-methyl-succinyl]-L-phenylalanine-N-methylamide 23. [4-(N-Hydroxyamino)-2R-isobutyl-3S-2-thienylsulphonyl-methyl-succinyl]-L-phenylalanine-N-methylamide 24. [4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylsulphonyl-methyl-succinyl]-L-phenylalanine-N-methylamide sodium salt 25. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(isobutyloxy-carbonylamino)phenyl)thiomethyl-succinyl]-L-phenyl-a~laniff~-N-methyla~ide llc 26. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(N-methyl-N-(tert-butoxycarbonyl)-glycylamino)phenyl)thiomethyl-succinyl]-L-phenylalanine-N-methylamide and, where appropriate, their salts. Compounds 2 and 5 are especially preferred and compound 2 is the most preferred, because of its good collagenase-inhibiting and protoglycanase-inhibiting activities.

Compounds of general formula I may be prepared by any suitable method known in the art and/or by the following process, which itself forms part of the invention.

According to a second aspect of the invention, there is provided a process for preparing a compound of general formula I as defined above, the process comprising:

(a) deprotecting a compound of general formula II

xl H J~
o A CON~IZ
I (II) RlSOn wherein:

Rl, R2, R3, R4, R5, A and n are as defined in general formula I and Z represents a protected hydroxy group such as a benzyloxy group; or (b) reacting a compound of general formula III

A COOII (III) Rl S~n wherein:

R1, R2, R3, R4, R5, A and n are as defined in 200;~18 general formula I, with hydroxylamine or a salt thereof; or (c) reacting a compound of general formula VIA
~ R3 R X~ N /~ NR4R5 CONHOH (VIA) wherein R2, R3, R4 and R5 are as defined in general formula I, either with a thiol of the general formula R1S, wherein R1 is as defined in general formula I to give a compound of general formula I in which A represents a methylene group and n is 0, or with a cuprate of the general formula (RlS-A1)2CuLi, wherein R1 is as defined in general formula I and Al is such that -A1-CH2- is identical to -A-, as defined in general formula I.

(d) optionally after step (a), step (b) or step (c) converting a compound of general formula I into another compound of general formula I.

Compounds of general formula I which are sulphoxides or sulphones can be derived from thiol compounds of general formula I by oxidation. Alternatively, thiols X003~718 of general formula II or III may be oxidised.

Oompounds af g~neral fo~mula T which are clit;~.llphlde~ (ie compound~ wherein R~ represents S~X) m~y ~e derived from thiol et.;t.cl!; t)r gener~l ~ormul~ I hy mild oxidation, for ex~ml~le ih air.

A compound of general formula II may be prepared from a compound of general formula III by reaction with an 0-protected (such as benzyl) hydroxylamine. A compound of general formula III may be prepared by desterification (such as hydrolysis) of an ester of the general formula R ~ ~ N ~ NR R

A CO R
R S~n 2 (IV) wherein:

Rl, R2, R3, R4, R5, A and n are as defined in general formula I and R6 represents Cl-C6 alkyl, phenyl Cl-C6 alkyl or substituted phenyl Cl-C6 alkyl.

- Z0037~8 -14a-A compound of general formula IV can be prepared from an ester of general formula V or an acid of general . formula VI
O R NR4R5 R2 ~ R3 H ~ ~ ~ H

(V) (VI) wherein:

R2, R3, R4 and R5 are as defined in general 2003~18 formula I and R6 represents Cl-C6 alkyl, phenyl C1-C6 alkyl or substituted phenyl Cl-C6 alkyl by reaction with a thiol RlSH, wherein Rl is as defined in general formula I, to give compounds wherein A
represents a methylene group, or by reaction with a cuprate of the general formula (RlS-Al)2CuLi, wherein Rl is as defined in general formula I and Al is such that -A1-CH2- is identical to -A-, as de~ined in general formula 1.

Esters of general formula V can be prepared by esterifying acids of general formula VI with an ~ appr~priate alcohol R60H or other esterifying agent.

Compounds of general formula VIA can be prepared by reacting compounds of general formula VI with hydroxylamine or a salt thereof.

An acid of general formula VI can be prepared by reacting a malonic acid derivative of general formula O R

~ H
HOOC COOH
(VII) wherein:

R2, R3, R~ and R5 are as defined in general formula I

.

- 200~7~8 with formaldehyde in the presence of pyridine.

An acid of general formula VII can in turn be prepared by desterifying (for example hydrolysing) a compound of general formula VIII

xl '~1~
R 02C 2 (VIII) wherein:

R2, R3, R4 and R5 are as defined in general formula I and R6 represents C1-C6 alkyl, phenyl Cl-C6 alkyl or substituted phenyl C1-C6 alkyl.

A compound of general formula VIII can be prepared by reacting a compound of general formula IX with a compound of general formula X

R ~ CCOH

R602C ~ C02R6 H2N CONR R
(IX) (X) wherein:

R2, R3, R4 and R5 are as defined in general formula I and R6 represents Cl-C6 alkyl, phenyl Cl-C6 alkyl or substituted phenyl Cl-C6 alkyl.

Z003~1?3 The starting materials and other reagents are either available commercially or can be synthesised by simple chemical procedures.

For example, a substituted acid of general formula IX
may be prepared by reacting an ester of the general formula XI

(XI~

- wherein Y represents halo and R5 is as defined above and R2 and R6 as defined above, with a malonate derivative of the general formula XII

(XII) wherein R6 is as defined above with the proviso that when R6 is aromatic in general formula XI it is aliphatic in general formula XII or vice versa, and selectively de-esterifying.

Compounds of general formula XI can simply be derived from amino acids, which can be obtained in enantiomerically pure form, enabling a choice of optically active compounds of general formula I to be prepared.

Compounds of general formulae II and III are valuable intermediates in the preparation of compounds of .

200371~3 general formula I. According to a third aspect of the invention, there is therefore provided a compound of general formula II. According to a fourth aspect of the invention, there is provided a compound of general formula III.

As mentioned above, compounds of general formula I are useful in human or veterinary medicine as they are active inhibitors, of metalloproteases involved in tissue degradation.

According to a fifth aspect of the invention, there is provided a compound of general formula I for use in human or veterinary medicine, particularly in the management (by which is meant treatment of prophylaxis~
of disease involving tissue degradation, in particular rheumatoid arthritis, and/or in the promotion of wound healing.

According to a sixth aspect of the invention, there is provided the use of a compound of general formula I in the preparation of an agent for the management of disease involving tissue degradation, particularly rheumatoid arthritis, and/or in the promotion of wound healing. Compounds of general formula I can therefore be used in a method of treating disease involving tissue degradation, particularly rheumatoid arthritis, and/or in a method of promoting wound healing, the method in either case comprising administering to a human or animal patient an effective amount of a compound of general formula I.

The potency of compounds of general formula I to act as inhibitors of collagenase (a metalloprotease involved in tissue degradation) was determined by the procedure of Cawston and Barrett, (Anal. Bioehem., 99, 340-34~, 1979) and their potency to aet as inhibitors of stromelysin was determined using the procedure of Cawston et al (Biochem. J., 195, 159-165 1981), both of which techniques are to be described more fully in the examples.

According to a seventh aspeet of the invention, there is provided a pharmaceutical or veterinary formulation eomprising a compound of general formula I and a pharmaceutically and/or veterinarily aeeeptable earrier. One or more eompounds of general formula I may be present in assoeiation with one or more non-toxie pharmaeeutieally and/or veterinarily aeeeptible earriers and/or diluents and/or adjuvents and if desired other active ingredients.

Aecording to an eighth aspeet of the invention, there is provided a process for the preparation of a pharmaceutical or veterinary formulation in aeeordanee with the seventh aspeet, the process comprising admixing a compound of general formula I and a pharmaceutically and/or veterinarily aceeptable earrier.

Compounds of general formula I may be formulated for administration by any route and would depend on the disease being treated. The compositions may be in the form of tablets, capsules, powders, qranules, lozenges, liquid.or gel preparations, such as oral, 200371~3 topical, or sterile parental solutions or suspensions.

Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrollidone; fillers for example lactose, sugar, maize-starch, calcium phosphate,sorbitol or glycine; tabletting lubricant, for example magnesium sterate, talc, polyethylene glycol or silica; disintegrants, for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain coventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin, hydrogenated edible' fats; emulsifiying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqujeous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired - 30 conventional flavouring or colouring agents.

The dosage unit involved in oral administration may .

.

contain from about 1 to 250 mg, preferably from about 25 to 250 mg of a compound of general formula I. A
suitable daily dose for a mammal may vary widely depending on the condition of the patient. However, a dose of a compound of general formula I of about 0.1 to 300mg/kg body weight, particularly from about 1 to 100 mg/kg body weight may be appropriate.

For topical application to the skin the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations that may be used for the drug are conventional fomulations well known in the art, for example, as described in standard text books of pharmaceutics such as the British Pharmacopoeia.

For topical applications to the eye~ the drug may be made up into a solution or suspension in a suitable sterile aqueous or non-aqueous vehicle. Additives, for instance buffers such as sodium metabisulphite or disodium edeate; preservatives including bactericidal and fungicidal agents, such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorohexidine, and thickening agents such as hypromellose may also be included.

The dosage employed for the topical administration will, of course, depend on the size of the area being treated. For the eyes each dose will be typically in the range from 10 to 100 mg of the compound of general formula I.

The active ingredient may also be administered parenterally in a sterile medium. The drug .

Z00~7~8 depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
Advantageously, adjuvants such as a local anasthetic, preservative and buffering agents can be dissolved in the vehicle.

- For use in the treatment of rheumatoid arthritis the compounds of this invention can be administered by the oral route or by in~ection intra-articularly into the affected joint. The daily dosage for a 70 kg mammal will be in the range of lO mgs to 1 gram of a compound of general formula I.

The following examples illustrate the invention, but are not intended to limit the scope in any way. The following abbreviations have been used in the Examples:-DCC - Dicyclohexylcarbodiimide DCM - Dichloromethane DCU - Dicyclohexylurea DIPE - Diisopropyl ether DMF - N,N-dimethylformamide HOBT - Hydroxybenztriazole NMM - N-Methylmorpholine TFA - Trifluoroacetic acid THF - Tetrahydrofuran WSCDI - N-(Dimethylaminoethyl)-N'-ethylcarbodiimide Example 1 t4-(N-Hydroxyamino)-2R-isobutyl-3S-(phenylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide .

Z00;~7~8 O
~ N ~ e o ~ CONHOH
rhS
a) 2R-Bromo-5-methylpentanoic acid.

D-Leucine (lOOg, 0.76 mol) and potassium bromide (317.5g, 2.67 mol) were dissolved in aqueous acid (150ml concentrated sulphuric acid in 500ml of water).
The solution was cooled to -2~ and sodium nitrite (69.6g, 0.95 mol in water) was added over lh taking care to maintain the temperature between -1 and -2~.
After addition was complete the mixture was kept at 0~
for a further hour, then DCM was added and the mixture stirred for a few minutes. The layers were separated and the aqeous phase was washed with further portions of DCM (5 x 250ml). The combined organic layers were dried over magnesium sulphate then the solvent removed to give the acid as a pale yellow oil (123.lg, 0.63 mol, 83~) [alpha]D = +38.0~ (c = 2, methanol) deltaH (250 MHz, CDC13) 4.29 (lH, t, J= 6.5Hz, BrCHC02H), 1.91 (2H, t, J= 7Hz, CHCH2CH), 1.83 (lH, m, Me2CH), and 0.94 (6H, 2xd, J= 7Hz, (CH3)2CH) b) tert-Butyl 2R-Bromo-5-methylpentanoate.
.

2R-Bromo-5-methylpentanoic acid (123g, 0.63 mol) .

20037~8 was dissolved in DCM (400ml) and the solution cooled to -40~ while isobutene was condensed in to roughly double the volume. Maintaining the temperature at -40~ concentrated sulphuric acid (4ml) was added dropwise. When the addition was complete the reaction was allowed to warm to room temperature overnight. The resultant solution was concentrated to half the volume by removing the solvent at reduced pressure, then the DCM was washed twice with an equal volume of 10% sodium bicarbonate solution. The organic layer was dried over magnesium sulphate and the solvent removed under reduced pressure to leave the title compound as a yellow oil (148.0g, 0.59 mol, 94%).

[alpha~D = +23.0~ (c = 2, methanol) deltaH (250 MHz, CDC13) 4.18 (lH, t, J= 6.5Hz, BrCHC02H), 1.89 (2H, m, CHCH2CH), 1.78 (lH, m, Me2CH), 1-49 (9H, s, (CH3)3C) and 0.94 (6H, 2xd, J= 7Hz, (CH3)2cH) deltac (63.9 MHz, CDC13) 167.0, 82.0, 46.3, 43.4, 27.6, 26.3, 22.2, and 21.6.

c) Benzyl (2-benzloxycarbonyl-3R-(tert-butoxycarbonyl)-5-methylhexanoate.

Dibenzyl malonate (124.5g, 0.44 mol) was taken up in dry DMF and potassium tert-butoxide (49-2g, 0.44 mol) was added portionwise with stirring and cooling.
When a homogeneous solution had formed it was cooled to o~ then tert-butyl-2R-bromo-5-methylpentanoate (llO.Og, 0.44 mol) in DMF (200 ml) was added dropwise .

over lh. When addition was complete the reaction was transfered to a cold room at <5~ and left for 4 days.
The reaction mixture was partitioned between ethyl acetate and saturated ammonium chloride then the aqueous layer extracted with further ethyl acetate (4x500ml), drying and solvent removal left an oil (228g) heavily contaminated with DMF. This oil was taken into ether (1 litre) and washed with brine (2xll) then the organic layer dried (magnesium sulphate), solvent removed under reduced pressure to leave the desired material (179g~ contaminated with a small amount of dibenzyl malonate.

talpha]D = +22.5~ (c = 2, methanol) deltaH (250 MHz, CDC13) 7.40 - 7.25 (lOH, m, Aromatic H), 5.14 (4H, 2xABq, CH2Ph), 3.77 (lH, d, J= lOHz, BnO2CCHC02Bn), 3.09 (lH, dt, J= 10,6Hz, CH2C_C02tBu), 1.50 (3H, m, CH2 + CHMe2)1.41 (9H, s, C(C_3)3) and 0.88 (6H, 2xd, J= 7Hz).

d) [4-Benzyloxy-3-benzyloxycarbonyl-2R-isobutyl-succinyl]-L-phenylalanine-N-methylamide Benzyl(2-benzyloxycarbonyl-5-methyl-3R-tert-butoxy-carbonyl)-hexanoate (281.4g, 0.56 mol) was taken up in 5% water in TFA (410 ml) and allowed to stand at 5~
overnight. After this time the TFA was evaporated under reduced pressure then the residue partitioned between DCM (11) and brine (200ml). Solvent removal left an oil which crystallised on standing (230g).

The crude acid from this reaction was dissolved in DMF

~00;~718 (11), then HOBT (95.3g, 0.64 mol), NMM (64g, 0.64 mol) and phenylalanine-N-methylamide (113.0g, 0.64 mol) were added at room temperature. The mixture was cooled to 0~ before dropwise addition of DCC (131.0g, 0.64 mol) in THF (11). This solution was stirred to room temperature over the weekend. The precipitated DCU was removed by filtration then the solvents were removed from the filtrate under reduced pressure to leave an oil. This oily residue was dissolved in ethyl acetate then washed with 10% citric acid, 10% sodium bicarbonate and saturated brine. The organic layer was dried (magnesium sulphate), filtered then the solvent removed under reduced pressure to give the title compound as an oil (400g). This material was columned on silica using gradient elution (0 - 50% ethyl acetate in hexane) to remove impurities and separate a small amount of the minor diastereoisomer. The material from the column (195g) was recrystallised from DIPE to give the title compound as a white crystalline solid (140.2g, 0.25 mol, 47%) m.p. 98 -99~
Analysis calculated for C33H38N2O6 Requires C 70.95 H 6.86 N 5.01 Found C 70.56 H 6.89 N 5.06 deltaH (250MHz, CDCl3) 7.42 - 7.13 (15H ,m, Aromatic H), 6.58 (lH, d, J=7.7Hz, CONH), 5.75 (lH, m, CONHMe), 5.20 - 5.05 (4H, m, OC_2Ph), 4.50 (lH, dt, J=
6.9,7.7Hz, CHCH2Ph), 3.79 (lH, d, J= 9.1Hz, CH(CO2Bn)), 3.15 - 2.91 (2H, m, C_2Ph), 2.65 (3H, d, J=
4.8Hz, CONHC_3), 1.52 (lH, m, CHCH2CH), 1.32 (lH, m, CH(CH3)), 1.05 (lH, m, CHCH2CH), and 0.74 (6H, 2xd, J=

200;~7~8 6.5Hz, CH(CH3)2) e) [4-Hydroxy-2R-isobutyl-3-ethenylsuccinyl]-L-phenyl-alanine-N-methylamide.

t4-Benzyloxy-3-benzyloxycarbonyl-2R-isobutylsuccinyl]-L-phenylalanine-N-methylamide (29.6g, 53mmol) was taken up in ethanol, ammonium formate (16.7g, 265mmol) added followed by 10% palladium on charcoal (6g) as a slurry in isopropyl alcohol. After 30 minutes at room temperature the catalyst was removed by filtration, then washed with ethanol to give a solution of the crude diacid. To this was added piperidine (5.0g) and the mixture stirred at room temperature for 15 minutes befDre addition of aqueous formaldehyde (40%
solution, 25ml). After 18 hours at room temperature the mixture was refluxed for 1 h. Solvents were removed under reduced pressure and the residue partitioned between ethyl acetate and citric acid.
The acid layer was extracted with further portions of ethyl acetate (2x250ml), the combined organic layers were extracted with potassium carbonate (3x200ml).
These base extracts were acidified to pH 4 and re-extracted with DCM' then the organic layer dried over magnesium sulphate. Solvent removal under reduced pressure gave the desired product as a white solid (9.35g, 27.0mmol, 51%).

m.p. 149-151~C

deltaH (250MHz, CDC13) 8.37 (2H, d, J= 9.OHz, CONH), 7.39 (lH, m, CONHMe), 7.27 - 7.06 (5H, m, Aromatic H), 6.40 (lH, s, CH2CHCO2H), S.78 (lH, s, CH2CHCO2H), 4.93 (lH, q, J= 7Hz, CHCH2Ph), 3.92 (lH, m, CH2CHCONH), 2.95 (2H, m, CH2Ph), 2.71 (3H, d, J= 4.1Hz, NHCH3), 1.68 (lH, m), 1.45 (2H, m), and 0.86 (6H, 2xd, J=
s.8Hz, CH(cH3)2j-deltac (63.9Hz, CDCl3) 173.3, 172.8, 169.6, 139.1, 136.3, 129.2, 128.3, 127.0, 126.6, 54.4, 43.5, 41.4, 39.1, 26.2, 25.7, 22.5 and 22.4 f) [4-Hydroxy-2R-isobutyl-3S-(phenylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide [4-Hydroxy-2R-isobuty-3-ethenylsuccinyl]-L-phenyl-alanine-N-methylamide (15.0g, 44mmol) was dissolved in thiophenol (150ml) and the mixture stirred in the dark under nitrogen at 60~ for 2 days. Ether was added to the cooled reaction mixture and the precipitated product collected by filtration. The solid was washed with large volumes of ether and dried under vacuum to give the title compound (13.1g, 28.7mmol, 65%).

m.p. 199-201~C
Analysis calculated for C25H32N2O4S
Requires C 65.76 H 7.06 N 6.14 S 7.02 Found C 65.69 H 7.06 N 6.07 S 7.05 deltaH (250MHz, D6-DMSO) 8.40 (lH, d, J= 9Hz, CONH), 7.82 (lH, m, CONHMe), 7.35 - 7.10 (7H, m, Aromatic H), 7.04 (3H, m, Aromatic H), 4.62 (lH, m, C_CH2Ph), 2.94 (lH, dd, J= 14,5Hz, CHCH2Ph), 2.89 (lH, dd, J=
14,9Hz, CHC_2Ph), 2.62 (3H, d, J= 4.5Hz, CONHC_3), 2.41 (3H, m, 2xCH + CH2SPh), 2.23 (lH, d, J= 12Hz, CH2SPh), 1.43 (lH, m, CHC_2CH), 1.30 (lH, bm, CH(CH3)2), 0.90 (lH, m, CHCH2CH) and 0.78 (6H, 2xd, J= 6.5Hz, CH(CH3)2.

g) [4-(N-Hydroxyamino)-2R-isobutyl-3S-(phenylthio-methyl) succinyl]-L-phenylalanine-N-methylamide [4-Hydroxy-2R-isobutyl-3S-(phenylthiomethyl)succinyl]
L-phenylalanine-N-methylamide (16.8g, 37 mmol) and HOBT (6.6g, 44 mmol) were dissolved in DCM / DMF
(4:1) and the mixture cooled to 0~ before adding WSCDI
(8.5g, 44 mmol) and NMM (4.5g, 44 mmol). The mixture was stirred at 0~ for lh to ensure complete formation of the activated ester. Hydroxylamine hydrochloride - (3.8g, 55 mmol) and NMM (5.6g, 55 mmol) were dissolved in DMF then this mixture added dropwise to the cooled solution of the activated ester. After lh the reaction was poured into ether / water (1:1) whereupon the desired product precipitated as white crystals. These were collected by filtration, further washed with ether and water then dried under vacuum at 50~. This material was recrystallised from methanol / water (1:1) to remove a trace of the minor diastereomer (9.03g, 19.2 mmol, 52~

m.p. 227-229~C

[alpha]D = -88~ (c = 10 , methanol) deltaH (250MHz, D6-DMSO) 8.84 (lH, d, J= 1.5Hz, NHOH), 8.35 (lH, d, J= 8.7Hz, CON_), 7.87 (lH, m, CONHMe), 7.29 - 6.92 (llH, m, Aromatic H + N_OH), 4.60 (lH, m, CHCH2Ph), 2.94 (lH, dd, J= 13.5,4.3, CHCH2Ph), 2.77 (lH, dd, J= 13.5,10, CHCII2Ph), 2.60 (3H, d,J= 4.6Hz), 2.53 (lH, m), 2.41 (lH, m), 2.20 (lH, dd, J=
13.4,2.2I~z, CHzSPh), 2.09 (lII, dd, J=13.4,2.4I~z, CII2SPII), 1.38 (2IT, m, CIIMe2 ~ CI~CIT2CII), 0.88 (lII, m, CIICIT2CII), 0.82 (3IT, d, J= ~ IIz, CII(CIT3)2), and 0.74 (3}1, d, J+ 6.4Hz, CII(C~T3)2).

de]tac (G3.9MHz, D6-DMSO) 172.9, 171.6, 166.3, 138.1, 136.7, 129.1, 128.9, 128.0, 127.3, 126.4, 125.2, 54.2, 46.4, 46.0, 37.7, 32.4, 25.6, 25.2, 24.2, and 21.7.

Example 2 [~-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthio-methyl) succinyl]-L-phenylalanine-N-methylamide o ,NH~l~

~CONHOH
,~S

a) [~-N-lIydroxy-2R-isobutyl-3S-(2-thienylthiomethyl) succinyl]-L-phenylalanine-N-methylamide .
The title compound was prepared from [4-Hydroxy-2R-isobutyl-3-ethenylsuccinyl]-L-phenylalanine-N-methyl-amide (400mg, 1.16mmol) by the method described in example lf, substituting 2-mercaptothiophene in the place of thiophenol to give a ma~erial (320mg, 0.73mmol, 63%) with the following characteristics.

m.p. 184-186~C

deltaII (250M~Iz, D6-DMSO) 8.29 (lII, d, J= 8.111z, CONH), 7.84 (lH, m, CONHMe), 7.57 (1~, d, J= 5.1Hz, Thiop~lene ~ 7.15 (5H, m, Aromatic H), 7.00 (2H, m, Thiophene }I), 4.50 (lI-I, m, CHCII2Ph), 2.91 (lII, m, CHCII2Ph), 2.75 (lII, m, CHCII2Ph), 2.56 (3II, d, J=
4.0Hz, CONIICH3), 2.34 (3H, m), 1.99 (lTI, d, J= 9.3Hz, cll2sllet)l 1.42 (lH, m, CHCH2CH), 1.29 (lII, bm, CII(CII3)2), 0.87 (lII, m, CHC}I2CII), 0.79 (311, d, J=
6.4Hz, CI~(CI-I3)2), and 0.72 (311, d, J= 6.4Hz, CH(CII3)2).

b) [4-(N-Hydroxyamino)-2R-isobutyl-3s-(2-thienylthio-methyl)succinyl]-L-phenylalanine-N-methylamide Prepared by the method described in example lg to give material with the following characteristics m.p. 236-238~C

Analysis calculated for C23H30N2O4S2 Requires C 57.84 11 6.54 N 8.80 Found C 57.64 I~ 6.48 N 8.85 deltaH (250MI~z, D6-DMSO) 8.80 (lH, s, CONIIOH), 8.08 (lH, d, J=8IIz, CONH), 7.52 (lH, m, CONHMe), 7.32 (lH, dd,. J= 4.6,2.9Hz, Thiophene H), 7.17 - 6.95 (511, m, l~romatic II), 6.89 (2H, m, Thiophene II), 4.46 (lII, m, NIICHCO), 2.89 (lII, dd, J=13.6,~.~Hz, CIICII2Ph), 2.72 (lII, dd, J= 13.6,10.511z, CIICH2Ph), 2.54 (3H, d, J=
4.3IIz, CONI-ICH3), 2.46 (lH, d, J= 12.1Hz, CH2S), 2.35 (lII, bt, J= 10.2Hz), 2.1~ (lII, bt, J= 10.2Hz), 1.98 (lII, dd, J=12.7,2.5Hz, CH2S), 1.35 (lII, bt, J=
11.41Iz, CHCH2CH), 1.22 ~lH, bm, CH(CH3)2), 0-86 (lII, bt, J=12.GHz, CIICH2CI~)~ 0.74 (3H, d, J= 6.3IIz, .;' ~

CA 02003718 1998-01-0~

CH ~C~13) 2), and 0.68 (3H, d, J= 6.~Hz, CH (C~13) 2)-deltac (63.9MHz, D6-DMSO) 172.5, 171.6, 166.1, 138.0, 133.8, 132.7, 129.4, 129.2, 128.1, 127.8, 126.5, 54.2, 46.2, 46.0, 38.5, 37.6, 25.8, 25.2, 24.2, and 21.7.

Fx~m~le 3 [4-(N-Hydroxyamino)-2R-isobutyl-3S-(benzylthiomethyl) succinyl]-L-phenylalanine-N-methylamide O ~ Ph ~, H
~ ~CONHOH
PhCH2S

Prepared by the method described in example lg to give material with the following characteristics Analysis calculated for C27H37N3Oss.o.5H2o Requires C 61.81 H 7.30 N 8.00 Found C 61.85 H 7.15 N 7.45 deltaH (250MHz, D6-DMSO) 8.40 (lH, s, CONHO~), 8.22 (lH, m, NHMe), 7.20 (5H, m. Aromatic H), 6.58 (4H, m), 4.10 (lH, m, CHC~2Ph), 3.22 (3H, s, OCH3), 3.04 - 2.45 (4H, m, 2xC~2Ar), 2.42 (3H, d, J= 6Hz, NHC~3), 2.32 - 2.08 (4H, m), 0.78 (2H, m, CHC~12CH), and 0.40 - 0.18 (7H, m, (C~3) 2C~).

Example 4 [4-(N-Hydroxyamino)-2R-isobutyl-3S-(acetylthiomethyl) succinyl]-L-phenylalanine-N-methylamide O
N ~l 1~ N ~t / \ . ~
~ONH(~
Ac~
Prepared by the method described in example lg to give material with the following characteristics m.p. 226-227~C

Analysis calculated for C21H31N3O5S.H2O
Requires C 55.37 H 7.30 N 9.22 Found C 55.57 H 6.99 N 9.53 deltaH (250MHz, D6-DMSO) 8.84 (lH, s, NHO_), 8.36 (lH, d, J= 8Hz, CONH), 7.80 (lH, d, J= 6Hz, NHMe), 7.20 (%h, m, Aromatic H), 4.58 (lH, m, CHCH2Ph), 3.16 - 2.62 (2H, ~, CHCH2Ph), 2.54 (3H, d, J= 4Hz, NHCH3), 2.22 (3H, 5, CH3COS), 2.36 - ~.10 (4H, m, CHCHCH2S), 1.36 (2H, m; CHCH2CH), and 0.98 - 0.66 (7H, m, CH(CH3)2).

Example 5 [4-(N-Hydroxyamino)-2R-isobutyl-3S-mercaptomethyl succinyl]-L-phenylalanine-N-methylamide O
~ H

~ C(~r\JH()H
., , 1~

Z00~718 .

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(acetylthiomethyl) succinyl]-L-phenylalanine-N-methylamide (3Omg, 0.06mmol) was stirred in methanol (3ml) with methylamine (lml methanolic solution) at room temperature. After 30 minutes the crystalline product (20mg, 0.05mmol, 74%) was filtered off and dried.

m.p. 234~C
Analysis calculated for C1gH39N304S.1.5H20 Requires C 54.10 H 7.63 N 9.94 S 7.60 Found C 54.28 H 7.16 N lD.43 S 7.80 deltaH (250MHz, D6-DMSO) 8.28 (lH, d, J= 9Hz, NHOH), 7.80 ~lH, m, NHMe), 7~22 (5H, m, Aromatic H), 4.6D (lH, m, CHCH2Ph), 3.08 - 2.56 ~2H, m, CHCH2Ph), 2.50 (3H, d, J= 4Hz, NHC 3), 2.40 - 2.02 (4H, m, CHCHCH2SH), 1.44 - 1.22 (2H, m, CHC_2CH) and 0.98 - 0.72 (7H, m, C-(CH3)2) ExamPle 6 ~4-(N-Hydroxyamino)-2R-isobutyl-3S-(benzoylthio-methyl)succinyl~-L-phenyialanine-N-methylamide P~

Nl1~1 - 20Q37~8 The title compound was prepared by the method described in Example lg to give material with the following characteristics m.p. 227 - 228~
Analysis calculated for C21H31N3O5S
Requires C 62.50 H 6.66 N 8.41 Found C 62.32 H 6.67 N 8.40 deltaH (250 MHz, CDC13:D6DMSO (1:1)) 8.82 (lH, s, NHOH), 8.25 (lH, d, J=8.4Hz, N_OH), 7.87 (2H, dd, J=8.5, l.lHz), 7.60 (2H, m, Ar-H and CON_), 7.50 (2H, t, J=8.2Hz), 7.28 (2H, d, J=8.4Hz), 7.16 (2H, t, J=7.2Hz), 7.04 (lH, t, J=8.5Hz), 4.65 (lH, m, CHCH2Ph), 3.06 (lH, dd, J=14.1, 5.0Hz, CHCH2Ph), 2.90 (lH, dd, J=13.9, 10Hz, CHC_2Ph), 2.73 (2H, m SC_2Ph), 2.65 (3H, d, J=4.7Hz, NHMe), 2.33 (lH, dt, J=11.0, 4.7Hz), 1.51 (lH, t, J=7Hz, CH2CHMe2), 1.24 (lH, m, CHMe2), 0.97 (lH, t, J=7Hz, CH2CHMe2), 0.84 (3H, d, J=6.5Hz, CHMe2) and 0.79 (3H, d, J=6.5Hz, CHMe23.

Exampl~ 7 - ~BI52 O
H~I~NHMe )NHOH
/~u ~S

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(pivaloylthiomethyl) succinyl]-L-phenylalanine-N-methylamide [4-Hydroxy-2R-isobutyl-3S-(pivaloylthiomethyl) succinyl]-L-phenylalanine-N-methylamide (0,8g, 1.7 mmol) and HOBT (0.3lg, 2.1 mmol) were dissolved in 1:1 DCM/DMF and the mixture cooled to 0~C before adding WSDCI (0.4g, 2.1 mmol) and NMM (0.21g, 2.1 mmol). The mixture was stirred at 0~C for lh to ensure complete formation of the activated ester. Hydroxylamine hydrochloride (0.18g, 2.6 mmol) and NMM (0.26g, 2.6 mmol) were dissolved in DMF then this mixture was added dropwise to the cooled solution of the activated ester. After lh the reaction was poured into ether/water (1:1) whereupon the desired product precipitated as white crystals. These were collected by filtration, further washed with ether and water, then dried under vacuum at 50~C. This material was recrystallized from methanol/water (1:1) to remove a trace of the minor diastereomer (0.38g, 0.7 mmol, 45%).

m.p. 225~C

~alpha] D = - 3.5~ (c=2, methanol) Analysis calculated for C24H39N3O5SØ5 H20 Requires: C58.99 H7.84 N8.60 Found: C58.96 H7.63 N8.55 deltaH (250MHz, D6-DMSO) 8.81 (lH, s, J=1.5Hz, NHOH), 8.30 (lH, d, J=8Hz, CONH), 7.78 (lH, d, J=6Hz, CONHMe), 7.27-7.03 (5H, m, aromatic H), 4.54 (lH, m, CHCH2Ph), 2.94 (lH, dd, J=12,5Hz, CHCH2Ph), 2.79 (lH, dd, J=13,10Hz, CHCH2Ph) 2.56 (3H, d, J=4.5Hz, NHC_3), 2.44 (2H, m), 2.20 (lH, dd, J=13,3Hz, CH2S), 2.07 (lH, dt), 1.36 (2H, m), 1.13 (9H, s, C(CH3)3), 0.87 (lH, m, CH2CH(CH3)2), 0.79 (3H, d, J= 6Hz, CH(C_3)2), and 0.74 (3H, d, J=6HZ, CH(CH3) 2)-deltac (63.9MHz, D6-DMSO) 172.55, 171.59, 168.24, 138.03, 129.18, 128.00, 126.24, 54.21, 46.48, 45.84, 45.55, 37.61, 28.30, 27.13, 25.64, 25.25, 24.24, and 21.63.

Example 8 - BB153 o f ~NHM~

~CONHONa PhS

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(phenylthiomethyl) succinyl]-L-phenylalanine-N-methylamide sodium salt.

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(phenylthiomethyl) succinyl]-L-phenylalanine-N-methylamide (0,2g, 0.4 mmol) was dissolved in 20 ml of methanol and 1 eq of 0.lN NaOH(aq) added.
The solvent was removed in vacuo and the residue dissolved in water and freeze dried (0.21g, 0.4 mmol, 100%).

m.p. 184~C

[alpha] D = -7-7~ (c=2, methanol) deltaH (250MHz, D6-DMSO) 8.62 (lH, s, J=1.5Hz, NHO_), 8.28 (lH, d, J-8Hz, CONH), 7.26 - 7.04 (lOH, m, aromatic H), 4.43 (lH, m, CHCH2Ph), 3.00 ~lH, dd, J=14,4Hz, CHCH2Ph), 2.84 (lH, dd, J=14,10Hz, CHCH2Ph), 2.55 (3H, d, J=4.5Hz, NHCH3), 2.46 (3H, m), 2.21 (lH, m), 1.39 (lH, m), 1.14 (lH, m), 1.00 (lH, m), and 0.70 (6H, d, J=5.7Hz) Example 9 - BB187 ~HJ~NHMe ~CONHOH

MeO

[4-(N-Hydroxyamino)-2R-isobutyl-3S-t4-methoxyphenylthiomethyl) succinyl]-L-phenylalanine-N-methylamide [4-Hydroxy-2R-isobutyl-3S-(4-methoxyphenylthiomethyl) succinyl]-L-phenylalanine-N-methylamide (0,5g, 1 mmol) and HOBT
(0.18g, 1.2 mmol) were dissolved in 1:1 DCM/DMF and the mixture cooled to 0~C before adding WSDCI (0.23g, 1.2 mmol) and NMM
(0.12g, 1.2 mmol). The mixture was stirred at 0~C for lh to ensure complete formation of the activated ester.
Hydroxylamine hydrochloride (O.lg, 1.5 mmol) and NMM (0.15g, 1.5 mmol) were dissolved in DMF then this mixture was added dropwise to the cooled solution of the activated ester. After 1 h the reaction was poured into ether/water (1:1) whereupon the desired product precipitated as white crystals. These were collected by filtration, further washed with ether and water, then dried under vacuum at 50~C. This material was recrystallised from methanol/water (1:1) to remove a trace of the minor diastereomer (0.36g, 0.7 mmol, 72~).

m.p. 225~C

[alpha] D = +8~ (c=0.5, methanol) Analysis calculated for C26H35N305S
Requires: C62.25 H7.04 N8.38 Found: C62.43 H7.09 N8.37 deltaH (250MHz, D6-DMSO) 8.83 (lH, s, J=1.5Hz, NHOH), 8.28 (lH, d, J=8Hz, CONH), 7.83 (lH, d, J=6Hz, CON_Me), 7.28 - 6.86 (9H, m, aromatic H), 4.52 (lH, m, CHCH2Ph), 3.73 (3H, s, OCH3), 2.91 (lH, dd, J=14, 4Hz, CHCH2Ph), 2.75 (lH, dd, J=14, lOHz, CHCH2Ph), 2.57 (3H, d, J=4.5Hz, NHCH3), 2.50 - 2.34 (2H, m), 2.16 - 1.99 (2H, m, CH2CH(CH3)2) 1.36 (2H, m), 0.88 (lH, m, C_2CH(CH3)2), 0.80 (3H, d, J=6Hz, CH(C_3)2), and 0.73 (3H, d, J=6HZ, CH(CH3)2)-deltac (63.9MHz, D6-DMSO) 172.79, 171.62, 168.39, 138.14, 131.34, 129.19, 128.00, 126.44, 114.59, 55.32, 54.20, 38.68, 25.63, 25.17, 24.26, and 21.70.

Example 10 - BB205 ~Ph NHMe ~CONHOH
~3~S

HO

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-hydroxyphenylthiomethyl) succinyl]-L-phenylalanine-N-methylamide [4-Hydroxy-2R-isobutyl-3S-(4-hydroxyphenylthiomethyl) succinyl]-L-phenylalanine-N-methylamide (0,4g, 0.8 mmol) and HOBT (0.15g, 1.0 mmol) were dissolved in 1:1 DCM/DMF and the mixture cooled to 0~C before adding WSDCI (0.20g, 1.0 mmol) and NMM (O.lg, 1.0 mmol). The mixture was stirred at 0~C for lh to ensure complete formation of the activated ester.
Hydroxylamine hydrochloride (0.09g, 1.3 mmol) and NMM (0.13g, 1.3 mmol) were dissolved in DMF then this mixture was added dropwise to the cooled solution of the activated ester. After lh the reaction was poured into ether/water (1:1) whereupon the desired product precipitated as white crystals. These were collected by filtration, further washed with ether and water, then dried under vacuum at 50~C. This material was recrystallised from methanoltwater (1:1) to remove a trace of the minor diastereomer (0.13g, 0.2 mmol, 31%).

m.p. 216~C

[alpha] D - -65~ (c-0.5, methanol) Analysis calculated for C25H33N3O5S
Requires: C61.58 H6.82 N8.62 Found: C61.43 H6.81 N8.08 deltaH (250MHz, D6-DMSO) 8.82 (lh, s, J=1.5Hz, NHO_), 8.26 (lH, d, J-8Hz, CONH), 7.81 (lH, d, J-6Hz, CON_Me), 7.27 - 6.64 (9H, m, aromatic H), 4.49 (lH, m, CHCH2Ph), 2.90 (lH, dd, J=14, 4Hz, CHCH2Ph), 2.74 (lH, dd, J=14, 10Hz, CHC_2Ph), 2.57 (3H, d, J=4.5Hz, NHCH3),2.54 - 2.29 (2H, m), 2.14 - 1.98 (2H, m, CH2CH(CH3)2), 1.35 (2H, m), 0.88 (lH, m, CH2CH(CH3)2), 0.80 (3H, d, J=6Hz, CH(C_3)2), and 0.73 (3H, d, J=6Hz, CH(CH3)2).

deltac (63.9MHz, D6-DMSO) 172.81, 171.66, 168.46, 156.50, 133.02, 132.17, 129.17, 128.02, 126.44, 124.17, 116.00, 54.20, 46.35, 46.13, 37.59, 35.40, 25.62, 25.16, 24.27, and 21.69.

ExamPle 11 - BB206 ~Ph O
~CONHON~
~S~,~S

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthiomethyl) succinyl]-L-phenylalanine-N-methylamide sodium salt [4-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthiomethyl) succinyl]-L-phenylalanine-N-methylamide (0,2g, 0.4 mmol) was dissolved in 20ml of methanol and leq of 0.lN NaOH(aq) added.
The solvent was removed in vacuo and the residue dissolved in water and freeze-dried (0.21g,0.4 mmol,100%).

m.p. 170~C

[alpha] D = - 67~ (c=l, methanol) deltaH (250MHz, d6-DMSO), 7.51 (lH, d, thiophene H), 7.19 -6.97 (8H, m, aromatic H), 4.32 (lH, m, CHCH2Ph), 3.00 (lH, dd, J = 14,4Hz, CHCH2Ph), 2.84 (lH, dd, J = 14,10Hz, CHCH2Ph) 2.53 (3H, d, J = 4.5Hz, NHCH3), 2.46 - 2.19 (3H, m), 1.37 (lH, m), 1.09 (lH, m), 0.93 (lH, m), and 0.67 (6H, m, CH2CH(CH3)2 Example 12 - BB212 ~J~N~N~IMe ~CONI-ION~

MeO~

~,..

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-methoxyphenyl-thiomethyl) succinyl]-L-phenylalanine-N-methylamide sodium salt [4-Hydroxyamino)-2R-isobutyl-3S-(4-methoxyphenylthiomethyl) succinyl]-L-phenylalanine-N-methylamide (0,lg, 0.2 mmol) was dissolved in 20ml of methanol and leq of 0.lN NaOH(aq) added. The solvent was removed ;n v~cuo and the residue dissolved in water and freeze-dried (0.lg, 0.2 mmol,100%).

m.p. 174~C

[alpha]D = -58~ (c=l, methanol) deltaH (250MHz, D6-DMSO 7.26 - 7.04 (lOH, m, aromatic H), 4.31 (lH, m, C~CH2Ph), 3.73 (3H, s, OCH3), 3.25 - 2.72 (2H, m, CHCH2Ph), 2.50 (3H, s, NHC~3), 2.36 (lH, m), 2.15 (lH, m), 1.37 (lH, m), 0.95 (lH, m), and 0.69 (6H, d, CHCH2(C~3) 2)-Fx~m~le 13 - RB257 H ~ NHMe CONHOH
~S

t~u~

CA 02003718 1998-01-0~

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-tertbutylphenyl-thiomethyl) succinyl]-L-phenylalanine-N-methylamide [4-Hydroxy-2R-isobutyl-3S-(4-tertbutylphenylthiomethyl) succinyl]-L-phenylalanine-N-methylamide (5.0g, 10 mmol) and HOBT (1.76g, 12 mmol) were dissolved in 1:1 DCM/DMF and the mixture cooled to 0~C before adding WSDCI (2.3g, 12mmol) and NMM (1.2g, 12mmol). The mixture was stirred at 0~C for lh to ensure complete formation of the activated ester.
Hydroxylamine hydrochloride (1.0g, 15mmol) and NMM (1.2g, 15mmol) were dissolved in DMF then this mixture was added dropwise to the cooled solution of the activated ester.
After lh the reaction was poured into ether/water (1:1) whereupon the desired product precipitated as white crystals. These were collected by filtration, further washed with ether and water, then dried under vacuum at 50~C. This material was repeatedly recrystallised from methanol/water (1:1) to remove a trace of the minor diastereomer (0.7g, 1.3mmol, 14~).

M.p. 188.5 -190 ~C

Analysis calculated for C29H4lN3O4S
Requiries: C66.00 H7.83 N7.96 Found: C65.80 H7.81 N7.76 deltaH (250MHz, D6-DMSO) 8.83 (lH, s, NHOH), 8.33 (lH, d, J
= 8Hz, CON~), 7.86 (lH, d, J= 6Hz, CON~Me), 7.28 - 6.90 (9H, m, aromatic H), 4.60 (lH, m, C~CH2Ph), 2.94 (lH, dd, J
= 14,4Hz, CHC~2Ph), 2.77 (lH, dd, J = 14,10Hz, CHCH2Ph), 2.58 (3H, d, J = 4.5Hz, NHC~3), 2.55 - 2.37 (2H, m), 2.22 -2.08 (2H, m, CH2CH(CH3)2), 1.37 (2H, m), 1.26 (9H, s, C(CH3)3), 0.88 (lH, m, C~2CH(CH3)2), 0.81 (3H, d, J = 6Hz, CH (C~3)2), and 0.74 (3H, d, J = 6Hz, CH(C~13) 2)-deltac (63.9MHz, D6-DMSO) 172.88, 171.59, 168.34, 147.87, 5 138.10, 133.09, 129.13, 127.95, 127.45, 126.36, 125.70, 54.19, 54.20, 46.38, 46.06, 37.70, 34.20, 32.79, 31.24, 25.64, 25.19, 24.25, and 21.72.

F.x~n~ le 14 - BR2~8 NI-~Me ~CONI~101-1 ~S

M~ ~ Me [4-(N-Hydroxyamino)-2R-isobutyl-35-(2,4-dimethylphenyl-thiomethyl) succinyl]-L-phenylalanine-N-methylamide [4-Hydroxy-2R-isobutyl-3S-(2,4-dimethylphenylthiomethyl) succinyl]-L-phenylalanine-N-methylamide (1.8g, 3.7 mmol) and HOBT (0.67g, 12 mmol) were dissolved in 1:1 DCM/DMF and the mixture cooled to 0~C before adding WSDCI (0.86g, 4.5 mmol) and NMM (0.45g 4.5mmol). The mixture was stirred at 0~C for lh to ensure complete formation of the activated ester. Hydroxylamine hydrochloride (0.39g, 5.6mmol) and NMM (0.56g, 5.6mmol) were dissolved in DMF then this mixture was added dropwise to the cooled solution of the activated ester. After lh the reaction was poured into ether/water (1:1) whereupon the desired product precipitated as white crystals. These were collected by filtration, further washed with ether and water, then dried under vacuum at 50~C. This material was repeatedly recrystallised from methanol/water (1:1) to remove a trace of the minor diastereomer (1.08~, 2.2mmol, 58~).

m.p. 226 ~C (dec.) Analysis calculated for C27H37N3O4S
Requires: C64.90 H7.46 N8.41 Found: C65.15 H7.48 N8.40 deltaH (250MHz, D6-DMSO) 8.83 (lH, s, NHO~), 8.32 (lH, d, J
= 8Hz, CON~), 7.85 llH, d, J = 6Hz, CON~Me), 7.30 - 6.71 (9H, m, aromatic H), 4.56 (lH, m, CHCHzPh), 2.91 (lH, dd, J
= 14,4Hz, CHC~2Ph), 2.76 (lH, dd, J = 14,10Hz, CHCH2Ph), 2.57 (3H, d, J = 4.5Hz, NHC~3), 2.53 - 2.38 (2H, m), 2.23 (3H, s, C6Hs(CH3) 2) 2.13 (3H, s, C6Hs(C~3), 1.30 (2H, m), 0.89 (lH, m, C~2CH(CH3)2), 0.81 (3H, d, J = 6Hz, CH(C~3)2), and 0.74 (3H, d, J = 6Hz, CH(C~3) 2)-Fx~mrle 15 - BB258 Ph H,~,NHM~

--CONHOH
r~
S
ONHO~ o ,~

S,S'-{[4(N-hydroxyamino)-2R-isobutyl-3S-(thiomethyl) succinyl]-L-phenylalanine-N-methylamide} disulphide [4-(N-Hydroxyamino-2R-isobutyl-3S-(acetylthiomethyl) succinyl]-L-phenylalanine-N-methylamide (l.Og, 2.4 mmol) was dissolved in 750ml methanol and 350ml pH 7 buffer added. Left to stand overnight and solvent removed in vacuo to 2/3 volume, left to crystallise for a further two hours. Filtered and dried to give 0.87g off-white crystals.

Analysis calculated for C38H56N60~S2.1.9H20 Requires: C55.34 H6.93 N9.88 Found: C55.44 H7.32 N10.21 Fx~le 16 - ~B 195 Ph O ~
'~f $1~ H ~ lH M e ~ CONHOI~
flr~ S

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(3-bromophenyl-thiomethyl) succinyl]-L-phenylalanine-N-methylamide Prepared by the method described in example lg to give material with the following characteristics.

m.p. 225 -229 ~C

[alpha] D = -164.8~

Analysis calculated for C2sH32BrN3O4S
Requires: C54.40 H5.89 N7.40 Found: C54.54 H5.86 N7.63 deltaH (250MHz, D6-DMSO) 8.83 (lH, s, NHO~), 8.35 (lH, d, J
= 8Hz, CONH), 7.90 (lH, q, J = 6Hz, CON~Me), 7.35 - 6.87 (9H, m, aromatic H), 4.64 (lH, m, CHCH2Ph), 2.94 (lH, dd, J
= 14,4Hz, CHCH2Ph), 2.76 (lH, t, J = 13Hz, CHC~2Ph) 2.60 10 (3H, d, J = 5Hz, NHC~3), 2.55 - 2.35 (2H, m, CH2S), 2.15 (lH, t, J = 10Hz, C~CO), 2.01 (lH, d, J = 11.5Hz, C~CO), 1.37 (2H, m), 0.88 (lH, m, C~2CH(CH3)2), 0.81 (3H, d, J =
6Hz, CH(C~3)2), and 0.74 (3H, d,J = 6Hz,CH(C~3)2).

deltac (63.9MHz, D6-DMSO) 173.0, 171.0 168.8, 139.8, 138.0, 15 130.5, 12~.0, 128.5, 127.5, 125.8, 125.5, 54.2, 46.0, 45.5, 38.0, 31.5, 25.5, 25.2, 24.7, and 21.0 F.x~m~l e 17 - BB 227 ~Ph H~NHMe ~CON~10 Cl ~ S ~

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(3-chlorophenyl-thiomethyl) succinyl]-L-phenylalanine-N-methylamide Prepared by the method described in example lg to give material with the following characteristics.

m.p. 231-234 ~C

[alpha] D = -96.5~

Analysis calculated for C25H32ClN3O4S
Requires: C59.34 H6.37 N8.30 Found: C59.51 H6.43 N8.24 deltaH (250MHz, D6-DMSO) 8.85 (lH, s, N~OH), 8.37 (lH, d, J
= 8.5Hz, CON~), 7.90 (lH, m, CON~Me), 7.30 - 6.88 (9Hj m, aromatic H), 4.66 (lH, m, CHCH2Ph), 2.96 (lH, bd, J = 14Hz, CHCH2Ph), 2.76 (lH, bt, J = 13Hz, CHC~2Ph) 2.60 (3H, d, J =
5Hz, NHC~3), 2.55 - 2.40 (2H, m, CH2S), 2.16 (lH, m, C~CO), 2.01 (lH, d, J = 14Hz, C~CO), 1.37 (2H, m), 0.91 (lH, m, C~2CH(CH3)2), 0.81 (3H, d, J = 6Hz, CH(C~3)2), and 0.74 (3H, d, J = 6Hz, CH (C~13)2)-deltac (63.9MHz, D6-DMSO) 172.7, 171.6, 168.1, 139.2, 138.1, 130.3, 129.2, 127.9, 126.2, 125.9, 125.5, 125.0, 54.1, 46.3, 45.8, 37.8, 32.0, 25.7, 25.2, 24.2, and 21.7 Fx~m~le 18 - RR 259 ,~,~JI~I-, ~NI-lMe ~C~ONHOH
Me ~S

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(3-methylphenylthio-methyl) succinyl]-L-phenylalanine-N-methylamide Prepared by the method described in example lg to give material with the following characteristics.

Analysis calculated for C26H35N3O4S
Requires: C64.30 H7.26 N8.65 Found: C63.81 H7.21 N8.48 deltaH (250MHz, D6-DMSO) 8.83 (lH, s, N~OH), 8.35 (lH, d, J
= 8.5Hz, CONH), 7.86 (lH, m, CONHMe), 7.28 - 6.77 (9H, m, aromatic H), 4.66 (lH, m, C~CH2Ph), 2.96 (lH, dd, J =
14,4Hz, CHCH2Ph), 2.80 (lH, bt, J = 13Hz, CHC~2Ph) 2.59 (3H, d, J = 5Hz, NHCH3), 2.55 - 2.37 (2H, m, C~2S), 2.16 (2H, m, 2xC~CO), 1.38 (2H, m), 0.91 (lH, m, CH2CH(CH3)2), 0.81 (3H, d, J = 6Hz, CH(C~3)2), and 0.74 (3H, d, J = 6Hz, CH(C~3)2).

Fx~m~le 19 - BB 343 NHMe ~CONI IOH
~I~S
~cNH ~

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(N-acetyl)-amino-phenylthiomethyl)succinyl]-L-phenylalanine-N-methylamide.

A) [2R-isobutyl-3S-(4-aminophenylthiomethyl)succinyl]-L-phenylalanlne-N-methylamide.

Prepared by the method described in example lf to give material with the following characteristics.

deltaH (250MHz, D6-DMSO) 8.27 (lH, d, J = 8.5Hz, CONH), 7.81 (lH, m, CON~Me), 7.30 - 7.00 (5H, m, phenyl H), 6.86 (2H, d, J = 8.5Hz, aromatic H), 6.45 (2H, d, J = 8.5Hz, aromatic H), 5.25 (lH, bs, CO2~), 4.48 (lH, m, CHCH2Ph), 2.91 (lH, dd, J = 14,4Hz, CHC~2Ph), 2.88 (lH, dd, J = 14,10Hz, CHC~2Ph) 2.56 (3H, d, J = 5Hz, NHC~3), 2.43 - 2.24 (3H, m, C~2S and C~CO), 2.03 (lH, d, J = 10Hz, C~CO), 1.41 (lH, t, J
= llHz, C~2CH(CH3)2), 1.26 (lH, m, CH2CH(CH3)2), 0.85 (lH, m, CH2CH(CH3) 2)r~ 81 (3H, d, J = 6Hz, CH(C~3) 2)r and 0.74 (3H, d, J=6Hz, CH(CH3) 2)-B) [2R-isobutyl-3S-(4-(N-acetyl)aminophenylthio-methyl)succinyl]-L-phenylalanine-N-methylamide.

The product from above (350mg, 0.74 mmol) was dissolved in DCM (5 ml) cooled in an ice bath then triethylamine (75mg, 0.74 mmol), DMAP (9lmg, 7.4 mmol) and finally acetic anhydride (83mg, 8.2 mmol) were added and the solution stirred at RT for 90 minutes. The mixture was partitioned between ethyl acetate and citric acid then the organic layer washed with water and finally dried over magnesium sulphate. Solvent removal gave the crude product as pale yellow crystals (160mg, 0.31 mmol, 42~).

CA 02003718 1998-01-0~

deltaH (250MHz, D6-DMSO) 9.94 (lH, s, CO2H), 8.34 (lH, d, J
= 8.5Hz, CON~), 7.90 (lH, m, CON~Me), 7.46 (2H, d, J =
8.5Hz, aromatic H) 7.30 - 7.00 (5H, m, phenyl H), 6.96 (2H, d, J = 8.5Hz, aromatic H), 4.57 (lH, m, C~CH2Ph), 2.91 (lH, dd, J = 14,4Hz, CHC~2Ph), 2.88 (lH, bt, J = 13Hz, CHC~2Ph), 2.58 (3H, d, J = 5Hz, NHC~3), 2.43 2.16 (3H, m, C~2S and C~CO), 2.10 (lH, d, J = 14Hz, CHCO), 1.35 (lH, t, J = 14Hz, CH2CH(CH3)2), 1.26 (lH, m, CH2C~(CH3)2), 0.86 (lH, m, CH2CH(CH3)2), 0.81 (3H, d, J = 6Hz, CH(C~3)2), and 0.74 (3H, d, J = 6Hz,CH(C~3) 2) C) [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(N-acetyl)-aminophenylthiomethyl)succinyl]-L-phenylalanine-N-methylamide.

Prepared by the method described in example lg to give material with the following characteristics.

m.p. 201 -202 ~C (dec.) [alpha] D = -7-5~ (c=1.0, methanol) deltaH (250MHz, D6-DMSO) 9.90 (lH, s, NHO~), 8.82 (lH, s, NHOH), 8.30 (lH, d, J = 8.5Hz, CON~), 7.85 (lH, m, CON~Me), 7.45 (2H, d, J = 8.5Hz, aromatic H), 7.28 - 6.94 (5H, m, phenyl H), 6.90 (2H, d, J = 8.5Hz, aromatic H), 4.66 (lH, m, C~CH2Ph), 2.90 (lH, dd, J = 14,4Hz, CHCH2Ph), 2.76 (lH, bt, J = 13Hz, CHC~2Ph), 2.50 (3H, d, J = 5Hz, NHC~3), 2.49 -2.35 (2H, m, CH2S), 2.14 (lH, m, CHCO), 2.03 (4H, s + m, COCH3 and C~CO), 1.35 (2H, m), 0.86 (lH, m, C~2CH(CH3)2), 0.81 (3H, d, J = 6Hz, CH(C~3)2), and 0.74 (3H, d, J = 6Hz, CH(C~13) 2)~

F.xi~ e 70 - BB 169 Pl 'I o ~ ONI-101-1 ¦ H
,SO
Pll [4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylsulfinylmethyl-succinyl]-L-phenylalanine-N-methylamide.

[4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylthiomethyl-succinyl]-L-phenylalanine-N-methylamide (250mg, 0.53mmol) was dissolved in methanol (50 ml) and meta-chloroperbenzoic acid (lOOmg, 0.58 mmol) was added. After stirring for lh at room temperature ether was added and the mixture filtered. Solvent removal gave the crude white solid which was recrystallised from methanol/water then slurried in ether to remove final traces of meta-chlorobenzoic acid to give the desired material (70 mg, 0.014 mmol, 27%).

m.p. 186 -188 ~C

[alpha]D = -13.6~ (c=0.5, methanol) Analysis calculated for C2sH33N3oss~o~5H2o Requires: C60.46 H6.90 N8.46 Found- C60.58 H6.69 N8.29 CA 02003718 1998-01-0~

deltaH (250MHz, D6-DMSO, mixture of diastereomers) 9.04 +
8.93 (lH, 2xs, N~OH), 8.29 + 8.16 (lH, 2xd, J = 8.5 Hz, CON~), 7.79 (lH, m, CON~Me), 7.90 - 7.40 (8H, m, aromatic H), 7.06, + 6.82 (2H, 2xm, SO-Aromatic), 4.37 (lH, m, C~CH2Ph), 2.93 - 2.58 (3H, m, containing CHC~2Ph), 2.52 (3H, m, NHCH3), 2.99 + 2.37 (lH, 2xm), 1.49 - 1.25 (2H, m, CH2CH(CH3)2) and CH2C~(CH3)2), 0.95 (lH, m, CH2CH(CH3)2), 0.81 (3H, d, J = 6Hz, CH(CH3)2), and 0.74 (3H, d, J=6Hz, CH(C113) 2)-deltac (63.9MHz, D6-DMSO, mixture of diastereomers) 172.2, 171.4, 171.3, 167.7, 144.5, 138.0, 137.9, 131.3, 130.9, 129.6, 129.3, 129.1, 128.8, 128.3, 127.8, 126.5, 126.2, 124.3, 123.6, 59.8, 58.1, 54.3, 54.0, 46.2, 45.8, 41.6, 40.9, 37.6, 37.4, 25.6, 25.0, 24.3, 24.2, 21.7, and 21.6.

Fx~le 21 - BB 170 Pll N~-~Me ~CON~IVI-l pl,~S~2 [4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylsulfonylmethyl-succinyl]-L-phenylalanine-N-methylamide.

[4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylthiomethyl-succinyl]-L-phenylalanine-N-methylamide (50mg, 0.11mmol) was dissolved in methanol (12 ml) and meta-chloroperbenzoic 53a acid (40mg, 0.23 mmol) was added. After stirring for 3h at room temperature ether was added and the mixture filtered.
Solvent removal gave the crude white solid which was slurried in ether to remove final traces of meta-chlorobenzoic acid to give the desired material.

m.p. 228 - 231~C

[alpha] D = 16.8~ (c=0.5, methanol) Analysis calculated for C2sH33N3o6s.o.3H2o Requires: C58.99 H6.65 N8.25 Found: C58.92 H6.51 N8.05 deltaH (250MHz, D6-DMSO)8.66 (lH, s, N~OH), 8.25 (lH, d, J =
8.5 Hz, CON~), 7.83 (lH, m, CON~Me), 7.75 - 7.50 (5H, m, aromatic H), 7.30 - 7.05 (5H, m, aromatic H), 4.36 (lH, m, CHCH2Ph), 2.86 (lH, dd, J = 14,5 Hz, CHC~2Ph), 2.75 (lH, dd, J = 14,10 Hz, CHC~2Ph), 2.54 t3H, d, J = 4.5 Hz, NHCH3), 2.54 (2H, m), 1.30 (2H, m, C~2CH(CH3)2 and CH2C~(CH3)2), 0.86 (lH, m, CH2CH(CH3)2), 0.75 (3H, d, J = 6Hz, CH(CH3)2), and O.71 (3H, d, J = 6Hz,CH (C~13) 2).

F.X~T~ e 22 -- B242 N

~SO

[4-(N-Hydroxyamino)-2R-isobutyl-3S-2-thienylsulphinylmethyl-succinyl]-L-phenylalanine-N-methylamide [4-(N-Hydroxyamino)-2R-isobutyl-3S-2-thienylthiomethyl-succinyl]-L-phenylalanine-N-methylamide (50mg, 0.11mmol) was treated as described in example 21 to yield the title compound (16mg, 0.03 mmol, 29%) as a mixture of diastereomer with the following characteristics:

m.p. 195 - 197~C (dec.) Analysis calculated for C23H3lN3Oss2~o~5H2o Requires: C54.96 H6.42 N8.36 Found: C54.91 H6.23 N8.23 deltaH (250MHz, D6-DMSO, mixture of diastereomers) 9.04 + 8.96 (lH, 2xs, NHOH), 8.34 + 8.29 (lH, 2xd, J = 8.5 Hz, CONH), 8.02 + 7.98 (lH, 2xm, CONHMe), 7.81 (lH, bs, thiophene-H), 7.42 (lH, s, thiophene-H), 7.25 - 7.15 (5H, m, phenyl), 7.03 (lH, bs, thiophene-H), 4.43 (lH, m, CHCH2Ph), 3.0 - 2.6 (4H, m, containing CHCH2Ph), 2.52 (7H, m, containing NHCH3), 2.05 (lH, m), 1.6 - 1.2 (2H, m, CH2CH(CH3)2 and CH2CH(CH3)2), 0.87 (lH, m, CH2CH(CH3)2), and 0.85 - 0.71 (6H, m, CH(CH3)2).
Example 23 - B250 ~Ph H J~ NHMe ONHOH
~S~SO2 [4-(N-Hydroxyamino)-2R-isobutyl-3S-2-thienylsulphonylmethyl-succinyl]-L-phenylalanine-N-methylamide.
[4-(N-Hydroxyamino)-2R-isobutyl-3S-2-thienylthiomethyl-succinyl]-L-phenylalanine-N-methylamide (75mg, 0.16mmol) was treated as described in example 22 to yield the title compound (40mg, 0.08 mmol, 49%) with the following characteristics:

m.p. 215 - 216~C

Analysis calculated for C23H3lN3O6S2 Requires: C54.21 H6.13 N8.24 Found: C54.07 H6.19 N8.04 delta~ (250MHz, D6-DMSO) 8.87 (lH, s, NHOH), 8.25 (lH, d, J =
8.5 Hz, CONH), 8.09 (lH, d, J = 4.7 Hz, thiophene-H), 7.83 (lH, m, CONHMe), 7.53 (lH, d, J = 3 Hz, thiophene H), 7.25 - 7.12 (6H, m, phenyl and thiophene-H), 4.36 (lH, m, CHCH2Ph), 3.38 (lH, dd, J = 14,11 Hz, SCH2~, 2.87 (lH, dd, J = 14,5 Hz, CHCH2Ph), 2.75 (lH, dd, J = 14,10 Hz, CHCH2Ph), 2.70 - 2.36 (6H, m, containing NHCH3), 1.20 (2H, m, CH2CH(CH3)2 and CH2CH(CH3)2), 0.89 (lH, m, CH2CH(CH3)2), and 0.75 (6H, m, CH(CH3) 2 ) -deltac (63.9MHz, D6-DMSO) 172.0, 171.2, 166.5, 140.0, 138.0, 135.4, 134.6, 129.0, 128.4, 128.2, 126.6, 54.3, 45.6, 37.5, 25.6, 25.0, 24.2, and 21.7.
Example 24 - B221 Pll N~Me - CO~ lONa ~SO2 ~,.

[4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylsulfonylmethyl-succinyl]-L-phenylalanine-N-methylamide sodium salt.

[4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylsulfonylmethyl-succinyl]-L-phenylalanine-N-methylamide (50mg, 0.lmmol) was dissolved in methanol (lOml) and sodium hydroxide solution (0.lM, l.Oml) added to give a homogeneous solution. The methanol was removed under reduced pressure then the residual aqueous solution freeze dried to give the title compound (4Omg).

deltaH (250MHz, D6-DMSO) 8.66 (lH, s, N~OH), 8.25 (lH, d, J
= 8.5 Hz, CON~), 7.83 (lH, m, CON~Me), 7.75 - 7.50 (5H, m, aromatic H), 7.30 - 7.05 (5H, m, aromatic H), 4.36 (lH, m, C~CH2Ph), 2.86 (lH, dd, J = 14,5 Hz, CHCH2Ph), 2.75 (lH, dd, J = 14,10 Hz, CHC~2Ph), 2.54 (3H, d, J=4.5 Hz, NHC~3), 2.54 (2H, m), 1.30 (2H, m, CH2CH(CH3) 2 and CH2CH(CH3) 2) ~ ~~ 86 (lH, m, CH2CH(CH3)2), 0.75 (3H, d, J = 6Hz, CH(C~3)2), and 0.71 (3H, d, J = 6Hz, CH(C~3) 2) Fx~m~le 25 - BB404 ~H J~ NHMe ~--CONHOI~

o CA 02003718 1998-01-0~

[4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(isobutyloxy-carbonylamino)phenyl)thiomethyl-succinyl]-L-phenylalanine-N-methylamide a) [4-Hydroxy-2R-isobutyl-3S-(4-amiinophenyl)thiomethyl-succinyl]-L-phenylalanine-N-methylamide was prepared by the method described in example lf to give a compound with the following characteristics.

deltaH (250 Mhz, D6-DMSO) 8.26 (lH, d, J = 8.5 Hz, COH~), 7.81 (lH, m, CONHMe), 7.27 - 7.15 (5H, m, phenyl H), 6.85 (2H, d, J = 8.5Hz, aromatic H), 6.46 (2H, d, J = 8.5Hz, aromatic H), 5.2 (lH, bs, CO2H), 4.48 (lH, m, C~CH2Ph), 2.90 (lH, dd, J = 13.5,4.3 Hz, CHCH2Ph), 2.75 (lH, dd, J =
13.6,10 Hz, CHC~2Ph), 2.56 (3H, d, J = 4.5 Hz, NHCH3), 2.50 - 2.25 (3H, m), 2.03 (lH, d, J = 10 Hz), 1.41 (lH, m, CH2CH(CH3)2), 1.26 (lH, m, CH2CH(CH3)2), 0.86 (lH, m, CH2CH(CH3)2), 0.75 (3H, d, J = 6Hz, CH(C~3)2), and 0.71 (3H, d, J = 6Hz,CH(CH3)2).

b) N,N-Dimethylglycine (lOOmg, 0.97 mmol) was stirred in dry THF (50ml) and triethylamine (108mg, l.lmmol) and isobutylchloroformate (146mg, l.lmmol) were added.
After lh the product from example 26a (500mg, l.lmmol) was added and the mixture stirred for a further lh.
The reaction was worked up by partitioning between citric acid and ethyl acetate, drying the organic layer and solvent removal to give the crude product (lg). Solution of the crude solid in ethyl acetate then precipitation with ether resulted in white crystals of the isobutylchloroformate derivative.

c) [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(isobutyloxy-carbonylamino)phenyl)thiomethyl-succinyl]-L-phenylalanine-N-methylamide The product from example 26b was converted to the hydroxamic acid as described in example lg to give a compound with the following characteristics.

m.p. 198 - 200 ~C

[alpha] D - -8.5~ (c=l, methanol) Analysis calculated for C30H42N4O6S
Requires: C61.41 H7.22 N9.55 Found: C62.04 H7.32 N9.67 delta~ (250MHz, D6-DMSO) 9.60 (lH, s, NHO~), 8.83 (lH, s, NHOH), 8.31 (lH, d, J = 8.5 Hz, CON~), 7.85 (lH, m, CONHMe), 7.36 - 7.25 (4H, m, aromatic H), 7.14 - 7.05 (3H, m, aromatic H), 6.91 (2H, d, J = 8.5Hz, aromatic H), 4.56 (lH, m, CHCH2Ph), 3.87 (2H, d, J = 7Hz, OCH2CH(CH3) 2) r 2.92 (lH, dd, J = 13.7,4.0 Hz, CHCH2Ph), 2.76 (lH, dd, J =
13.6,10 Hz, CHCH2Ph), 2.58 (3H, d, J = 4.5 Hz, NHC~3), 2.50 - 2.34 (2H, m), 2.16 - 1.87 (3H, m), 1.35 (2H, m, C~2CH(CH3)2 and CH2C~(CH3)2), 0.93 (6H, d, J = 6.6Hz, OCH2CH(C~3)2), 0.87 (lH,m, C~2CH(CH3)2), 0.75 (3H, d, J = 6Hz, CH(CH3)2), and 0.71 (3H, d, J = 6Hz, CH(CH3)2).

58a F.x~m~l e 26 - BB405 H~H NHMC

~I~C)NHOH
~N J~ s [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(N-methyl-N-(tertbutoxycarbonyl)-glycylamino) phenyl)thiomethyl-5 succinyl]-L-phenylalanine-N-methylamide.

a) [4-Hydroxy-2R-isobutyl-3S-(4-(N-methyl-N-(tert-butoxycarbonyl)-glycylamino) phenyl)thiomethyl-succinyl]-L-phenylaline-N-methylamide was prepared as described in example 26b by substitution of N-BOC sarcosine for the acid component.

delta~ (250MHz, D6-DMSO) 9.97 (lH, s, CO2H), 8.36 (lH, d, J =
8.5 Hz, CONH), 7.91 (lH, m, CONHMe), 7.48 (2H, d, J = 8.5Hz, aromatic H), 7.40 - 7.05 (5H, m, aromatic H), 6.97 (2H, d, J
= 8.5Hz, aromatic H), 4.58 (lH, m, CHCH2Ph), 3.95 (2H, d, J =
9Hz, NCH2CO), 2.92 (4H, m+d, CHCH2Ph and BOCNCH3), 2.76 (lH, dd, J = 13,10 Hz, CHCH2Ph), 2.58 (3H, d, J = 4.5 Hz, NHCH3), 2.50 - 2.09 (4H, m), 1.46 - 1.33 (llH, m + 2xs, (CH3)3 C, CH2CH(CH3)2 and CH2CH(CH3)2), 0.87 (lH, m, CH2CH(CH3)2 ), 0.75 (3H, d, J = 6Hz, CH(CH3)2), and 0.71 (3H, d, J = 6Hz, CH(CH3) 2 ) -b) [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(N-methyl-N-(tert-butoxycarbonyl)-glycylamino) phenyl)thiomethyl-succinyl]-L-phenylalanine-N-methylamide was prepared from the material produced in example 27a as described in example lg.

delta~ (250MHz, D6-DMSO) 9.97 (lH, s, CONHOH), 8.83 (lH, s, NHOH), 8.32 (lH, d, J = 8.5 Hz, CONH), 7.86 (lH, m, CONHMe), 7.46 (2H, d, J = 8.5Hz, aromatic H), 7.28 - 7.00 (5H, m, aromatic H), 6.97 (2H, d, J = 8.5Hz, aromatic H), 4.56 (lH, m, CHCH2Ph), 3.94 (2H, d, J = 9Hz, NCH2CO), 2.87 (4H, m+d, CHCH2Ph and BOCNCH3), 2.76 (lH, m, CHCH2Ph), 2.57 (3H, d, J =
4.5 Hz, NHCH3), 2.25 - 1.91 (2H, m), 1.42 - 1.30 (llH, m +
2xs, (CH3)3C, CH2CH(CH3)2 and CH2CH(CH3)2), 0.92 (lH, m, CH2CH(CH3)2 ), 0.80 (3H, d, J = 6Hz, CH(CH3)2), and 0.73 (3H, d, J=6Hz, CH(CH3)2).

~ V

59a Example 27 Collagenase inhibition activity The potency of compounds of general formula I to act as inhibitors of collagenase (a metalloproteas involved in tissue degradation) was determined by the procedure of Cawston and sarrett, (Anal. Biochem., 99, 340-345, 1979), whereby a lmM
solution of the inhibitor being tested or dilutions thereof was incubated at 37~ for 16 hours with collagen and collagenase (buffered with 25mM

Hepes, pH 7.5 containing 5mM CaCl2, 0.05% Brij 35 and 0.02% NaN3). The collagen was acetylated 14C collagen prepared by the method of Cawston and Murphy (Methods in Enzymology, 80, 711, 1981). The samples were centrifuged to sediment undigested collagen and an aliquot of the radioactive supernatant removed for assay on a scintillation counter as a measure of hydrolysis. The collagenase activity in the presence of 1 mM inhibitor, or a dilution thereof, was compared to activity in a control devoid of inhibitor and the results reported below as that inhibitor concentration effecting inhibition of the collagenase (IC50).

Compound of Example No. IC50 1 20 nM
2 8 nM
3 nM
6 (50% @ 1 mcM) Example 28 Stromelysin inhibition activity The potency of compounds of general formula I to act as inhibitors of stromelysin was determined using the procedure of Cawston et al (Biochem. J., 195, 159-165 1981), whereby a lmM solution of the inhibitor being tested or dilutions thereof was incubated at 37~C for 16 hours with stromelysin and 14C acetylate casein (buffered with 25mM Hepes, pH 7.5 containing 5mM CaCl2, 0.05% Brij 35 and 0.02% NaN3. The casein was 14C acetylated according to the method described in Cawston et al f ~

(Biochem. J., 195, 159-165, 1981). The stromelysin activity in the presence of lmM, or a dilution thereof, was composed to activity in a control devoid of inhibitor and the results reported below as that inhibitor concentration effecting 50% inhibition of the stromelysin ( IC50 ) -Compound of Example No. IC50 1 10 nM2 20 nM

Examples of unit dosage compositions are as follows:

Example 29 Capsules:
Per 10,000 Inqredients Per CaPsule Capsules 1. Active ingredient Cpd. of Form. I40.0 mg 400 g 2. Lactose 150.0 mg 1500 g 3. Magnesium stearate ~-4.0 mq 40 q 194.0 mg 1940 g Procedure for capsules:

Step 1. Blend ingredients No. 1 and No. 2 in a suitable blender.
Step 2. Pass blend from Step 1 through a No. 30 mesh (0.59 mm) screen.
Step 3. Place screened blend from Step 2 in a ..
~,-, ~.

2003~

suitable blender with ingredient No. 3 and blend until the mixture is lubricated.
Step 4. Fill into No. 1 hard gelatin capsule shells on a capsule machine.

Example 30 Tablets:
Per 10,000 Ingredients Per Tablet Tablets 1. Active ingredient Cpd. of Form. I 40.0 mg 400 g 2. Corn Starch 20.0 mg 200 g 3. Alginic acid 20.0 mg 200 g 4. Sodium alginate20.0 mg 200 g 5. Magnesium stearate 1.3 mq 13 g ' 101.3 mg 1013 g Procedure for tablets:
Step 1. Blend ingredients No. 1, No. 2, No. 3 and No.
4 in a suitable mixer/blender.
Step 2. Add sufficient water portionwise to the blend from Step 1 with careful mixing after each addition. Such additions of water and mixing until the mass is of a consistency to permit its conversion to wet granules.
Step 3. The wet mass is converted to granules by passing it through an oscillat-ing granulator using a No. 8 mesh (2.38) screen.
Step 4. The wet granules are then dried in an oven at 2003~7~8 140~F (60~C) until dry.
Step 5. The dry granules are lubricated with ingredient No. S.
Step 6. The lubricated granules are compressed on a suitable tablet press.

Example 31 Intramuscular Injection:
IngredientPer ml. Per liter 1. Compound of Formula I
Active ingredient 10.0 mg 10 g 2. Istonic buffer solution pH 4Ø q.s. q.s.

Procedure:
Step 1. Dissolve the active ingredient in the buffer solution.
Step 2. Aseptically filter the solution from Step 1.
Step 3. The sterile solution is now aseptically filled into sterile ampoules.
Step 4. The ampoules are sealed under aspetic conditions.

Example 32 Suppositories:
Per InqredientsPer SuPP.1,000 Supp 1. Compound of Form. I
Active ingredient 40.0 mg 40 g 2. Polyethylene Glycol 1000 1350.0 mg 1,350 g 3. Polyethylene Glycol 4000 450.0 mg 450 g 1840.0 mg 1,840 g Procedure:
Step 1. Melt ingredient No. 2 and No. 3 together and stir until uniform.
Step 2. Dissolve ingredient No. 1 in the molten mass from Step 1 and stir until uniform.
Step 3. Pour the molten mass from Step 2 into suppository moulds and chill.
Step 4. Remove the suppositories from moulds and wrap.

Example 33 Eye Ointment An appropriate amount of a compound of general formula I is formulated into an eye ointment base having the following composition:

Liquid paraffin 10%
Wool fat ' 10%
Yellow soft paraffin 80%

Example 34 Topical skin ointment An appropriate amount of a compound of general formula I is formùlated into a topical skin ointment base having the following composition:

Emulsifying wax 30 White soft paraffin 50~
Liquid paraffin 20%

Claims (48)

1. A compound of general formula I:

wherein:

R1 represents a C1-C6 alkyl other than tert-butyl; phenyl;
substituted phenyl wherein the substituents are selected from C1-C6 alkyl, hydroxy, C1-C6 alkoxy, C1-C6 alkylcarbonylamino, C1-C6 alkoxycarbonylamino and [N-(C1-C6 alkoxycarbonylamino)-N-(C1-C6 alkyl)] amino (C1-C6 alkylaminocarbonylamino);thienyl; (C1-C6) alkylcarbonyl;
or benzoyl group;

R2 represents a hydrogen atom or a C1-C6 alkyl, C2-C6 alkenyl, phenyl (C1-C6) alkyl, cycloalkyl (C1-C6) alkyl or cycloalkenyl (C1-C6) alkyl group;

R3 represents an amino acid side chain, a C1-C6 alkyl group other than an amino acid side chain, benzyl, (C1-C6 alkoxy) benzyl or benzyloxy (C1-C6 alkyl) or benzyloxy benzyl group;

R4 represents a hydrogen atom or a C1-C6 alkyl group;

R5 represents a hydrogen atom or a methyl group;

n is an integer having the value 0, 1 or 2; and A represents a C1-C6 hydrocarbon chain;

or a salt thereof ingestible by humans or animals.

2. A compound as claimed in Claim 1, in which the chiral centre adjacent the substituent R3 has S stereochemistry.

3. A compound as claimed in Claim 1 or 2, wherein the chiral centre adjacent the substituent R2 has R stereochemistry.

4. A compound as claimed in Claim 1 or 2, in which R1 represents a C1-C4 alkyl other than tertbutyl, phenyl, 4-hydroxyphenyl, thienyl, acetyl or benzoyl group.

5. A compound as claimed in Claim 3, in which R1 represents a C1-C4 alkyl other than tertbutyl, phenyl, 4-hydroxyphenyl, thienyl, acetyl or benzoyl group.

6. A compound as claimed in Claim 1, 2 or 5, wherein R2 represents a C3-C6 alkyl group.

7. A compound as claimed in Claim 3, wherein R2 represents a C3-C6 alkyl group.

8. A compound as claimed in Claim 4, wherein R2 represents a C3-C6 alkyl group.

9. A compound as claimed in Claim 1, 2, 5, 7 or 8, wherein R3 represents a benzyl or 4-(C1-C6)alkoxyphenylmethyl or benzyloxybenzyl group.

10. A compound as claimed in Claim 3, wherein R3 represents a benzyl or 4-(C1-C6)alkoxyphenylmethyl or benzyloxybenzyl group.

11. A compound as claimed in Claim 4, wherein R3 represents a benzyl or 4-(C1-C6)alkoxyphenylmethyl or benzyloxybenzyl group.

12. A compound as claimed in Claim 6, wherein R3 represents a benzyl or 4-(C1-C6)alkoxyphenylmethyl or benzyloxybenzyl group.

13. A compound as claimed in Claim 1, 2, 5, 7, 8, 10, 11 or 12, wherein R4 represents a C1-C4 alkyl group.

14. A compound as claimed in Claim 3, wherein R4 represents a C1-C4 alkyl group.

15. A compound as claimed in Claim 4, wherein R4 represents a C1-C4 alkyl group.

16. A compound as claimed in Claim 6, wherein R4 represents a C1-C4 alkyl group.

17. A compound as claimed in Claim 9, wherein R4 represents a C1-C4 alkyl group.

18. A compound as claimed in Claim 1, 2, 5, 7, 8, 10, 11, 12, 14, 15, 16 or 17, wherein R5 represents a hydrogen atom.

19. A compound as claimed in Claim 3, wherein R5 represents a hydrogen atom.

20. A compound as claimed in Claim 4, wherein R5 represents a hydrogen atom.

21. A compound as claimed in Claim 6, wherein R5 represents a hydrogen atom.

22. A compound as claimed in Claim 9, wherein R5 represents a hydrogen atom.

23. A compound as claimed in Claim 13, wherein R5 represents a hydrogen atom.

24. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(phenylthiomethyl)-succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthiomethyl) succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(acetylthiomethyl) succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(pivaloylthiomethyl) succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(phenylthiomethyl) succinyl]-L-phenylalanine-N-methylamide sodium salt, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-methoxyphenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-hydroxyphenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthio-methyl)succinyl]-L-phenylalanine-N-methylamide sodium salt, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-methoxyphenylthio-methyl)succinyl]-L-phenylalanine-N-methylamide sodium salt, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-tertbutylphenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(2,4-dimethylphenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(3-bromophenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(3-chlorophenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(3-methylphenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(N-acetyl)-aminophenyl-thiomethyl)succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylsulphinyl-methylsuccinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylsulphonyl-methylsuccinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-2-thienylsulphinylmethyl-succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-2-thienylsulphonylmethyl-succinyl]-L-phenylalanine-N-methylamide, [4-(N-Hydroxyamino)-2R-isobutyl-3S-phenylsulphonylmethyl-succinyl]-L-phenylalanine-N-methylamide sodium salt, [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(isobutyloxy-carbonylamino)phenyl)thiomethyl-succinyl]-L-phenylalanine-N-methylamide, or [4-(N-Hydroxyamino)-2R-isobutyl-3S-(4-(N-methyl-N-(tert-butoxycarbonyl)-glycylamino)phenyl)thiomethyl-succinyl]-L-phenylalanine-N-methylamide or, where appropriate, a salt ingestible by humans or animals of such a compound.

25. [4-(N-Hydroxyamino)-2R-isobutyl-3S-(2-thienylthio--methyl)succinyl]-L-phenylalanine-N-methylamide, or a salt thereof ingestible by humans or animals.

26. A compound as claimed in Claim 1, 2, 5, 7, 8, 10, 11, 12, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24 or 25 for use in human or veterinary medicine.

27. A compound as claimed in Claim 3 for use in human or veterinary medicine.

28. A compound as claimed in Claim 4 for use in human or veterinary medicine.

29. A compound as claimed in Claim 6 for use in human or veterinary medicine.

30. A compound as claimed in Claim 9 for use in human or veterinary medicine.

31. A compound as claimed in Claim 13 for use in human or veterinary medicine.

32. A compound as claimed in Claim 18 for use in human or veterinary medicine.

33. The use of a compound as claimed in Claim 1, 2, 5, 7, 8, 10, 11, 12, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24 or 25 in the preparation of an agent for use in the management of disease involving tissue degradation and/or in the promotion of wound healing.

34. The use of a compound as claimed in Claim 3 in the preparation of an agent for use in the management of disease involving tissue degradation and/or in the promotion of wound healing.

35. The use of a compound as claimed in Claim 4 in the preparation of an agent for use in the management of disease involving tissue degradation and/or in the promotion of wound healing.

36. The use of a compound as claimed in Claim 6 in the preparation of an agent for use in the management of disease involving tissue degradation and/or in the promotion of wound healing.

37. The use of a compound as claimed in Claim 9 in the preparation of an agent for use in the management of disease involving tissue degradation and/or in the promotion of wound healing.

38. The use of a compound as claimed in Claim 13 in the preparation of an agent for use in the management of disease involving tissue degradation and/or in the promotion of wound healing.

39. The use of a compound as claimed in Claim 18 in the preparation of an agent for use in the management of disease involving tissue degradation and/or in the promotion of wound healing.

40. A pharmaceutical or veterinary formulation comprising a compound as claimed in Claim 1, 2, 5, 7, 8, 10, 11, 12, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24 or 25 and a pharmaceutically and/or veterinarily acceptable carrier.

41. A pharmaceutical or veterinary formulation comprising a compound as claimed in Claim 3 and a pharmaceutically and/or veterinarily acceptable carrier.

42. A pharmaceutical or veterinary formulation comprising a compound as claimed in Claim 4 and a pharmaceutically and/or veterinarily acceptable carrier.

43. A pharmaceutical or veterinary formulation comprising a compound as claimed in Claim 6 and a pharmaceutically and/or veterinarily acceptable carrier.

44. A pharmaceutical or veterinary formulation comprising a compound as claimed in Claim 9 and a pharmaceutically and/or veterinarily acceptable carrier.

45. A pharmaceutical or veterinary formulation comprising a compound as claimed in Claim 13 and a pharmaceutically and/or veterinarily acceptable carrier.

46. A pharmaceutical or veterinary formulation comprising a compound as claimed in Claim 18 and a pharmaceutically and/or veterinarily acceptable carrier.

47. A process for preparing a compound of general formula I
as defined in Claim 1, the process comprising:

(a) deprotecting a compound of general formula II

wherein:

R1, R2, R3, R4, R5, A and n are as defined in general formula I and Z represents a protected hydroxy group; or (b) reacting a compound of general formula III

wherein:

R1, R2, R3, R4, R5, A and n are as defined in general formula I, with hydroxylamine or a salt thereof ingestible by humans or animals.

48. A compound of general formula III

wherein:

R1, R2, R3, R4, R5, A and n are as defined in general formula I as defined in Claim 1.